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ABSTRACT
Kisspeptins signal via the G-protein coupled receptor, KISS1R, and act as
metastasis suppressors in numerous cancers. In estrogen receptor (ERα)-negative breast
cancer cells, however, KISS1R signaling promotes cell invasion by activating the
epidermal growth factor receptor (EGFR). Unfortunately, clinical success of anti-EGFR
therapeutics has been limited, as patients often develop drug resistance.

Recently,

another receptor tyrosine kinase, AXL, has been shown to promote breast cancer drug
resistance. We hypothesize that KISS1R promotes EGFR expression and induces breast
cancer drug resistance. We demonstrated that KISS1R increases EGFR transcription, by
increasing SP-1 binding to the EGFR promoter, as demonstrated by chromatin
immunoprecipitation experiments. Additionally, we discovered that KISS1R signaling
promotes drug resistance of ERα-negative breast cancer cells, since KISS1R
overexpression decreased intracellular doxorubicin accumulation and decreased
sensitivity.

KISS1R also promotes AXL expression and AXL depletion restored

doxorubicin sensitivity. Overall, our results suggest that KISS1R signaling promotes
ERα-negative breast cancer drug resistance and may be a novel target to restore drug
sensitivity.

Key Words: Triple negative breast cancer (TNBC), drug resistance, KISS1R, kisspeptin
(KP), G-protein coupled receptor (GPCR), breast cancer, epidermal growth factor
receptor (EGFR), AXL, doxorubicin, MTT cell viability
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Chapter 1: Introduction
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1.1 Breast Cancer
According to the Canadian Cancer Society, breast cancer is the most commonly
diagnosed cancer among Canadian women and is the second leading cause of cancerrelated deaths in the country. Breast cancer affects 1 in 9 Canadian women and accounts
for 26% of all new diagnosed cancers in 2014. It is estimated that this year in Canada,
24,400 women and 210 men will be diagnosed with breast cancer, and 5,000 women are
expected to die from the disease†.
1.1.1 Breast Cancer Staging and Classification
Normal breast epithelium forms a well-defined uniform layer, forming milk ducts
or glands of the breast. In contrast to healthy cells, breast cancer cells have undergone
genetic changes, enabling them to develop a malignant phenotype. These cancer cells
exhibit specific alterations in cellular processes, including: decreased apoptosis and
immune destruction, as well as increased proliferation rate, invasion, and genomic
instability, resulting in tumourigenesis (1).

The genetic changes that drive

tumourigenesis are often acquired through spontaneous mutations, however they can also
be inherited. Approximately 5-10% of all breast cancers have a hereditary background
(2).

Germline mutations in BRCA 1/2, tumour suppressor genes implicated in

maintaining genomic stability through their role in DNA repair, increase the risk of
developing breast cancer by the age of 70 to 45-87% (3).
Breast cancer staging describes the extent or spreading of cancer in the body. The
American Joint Committee on Cancer (AJCC) has developed a classification system,
which describes the severity of a patient’s cancer based on the location and size of the
primary tumour and the metastatic extent. The initial stage, stage 0, is when abnormal

!

3!

breast cells are present, appearing as pinpoint lesions, yet a primary tumour cannot be
detected (4). Most often, breast cancers arise from abnormally proliferating cells in either
the duct lining or lobular tissue of the mammary glands and are referred to as ductal and
lobular hyperplasias, respectively. Once these cells begin to form a small mass, they are
respectively termed, ductal carcinoma in situ (DCIS) and lobular carcinoma in situ
(LCIS). As cancer progresses, cells become more aggressive and begin to invade into
surrounding tissues, the cancer is referred to as invasive ductal carcinoma (IDC) or
invasive lobular carcinoma (ILC). Stages I-III are classified based on the size of the
primary tumour and the degree that the breast cancer cells have spread to the lymph
nodes surrounding the breast (5). In the final stage, stage IV, breast cancer cells have
spread to distant organs or tissue sites, most often brain, bone, liver and lung, at which
point the cancer becomes extremely difficult to treat and patient prognosis is very poor
(4) (Figure 1.1).
Additionally, breast tumours can be described based on how abnormal the tumour
cells and tissue look under a microscope, termed tumour grade. Generally, tumours are
graded as 1, 2, 3 or 4, depending on the degree of abnormality. Grade 1 tumour cells
closely resemble normal breast tissue while Grade 4 tumour cells are highly abnormal or
undifferentiated. Grade 3 and Grade 4 tumours tend to grow rapidly and spread faster
than tumours with lower grade (6).

!

Figure 1.1.

4!

Breast cancer progression. Healthy normal epithelium cells undergo

genetic or epigenetic changes resulting in deregulated cell growth and ductal hyperplasia.
As cells begin to lose their normal morphology, they progress to an appearance indicative
of ductal carcinoma in situ. Continued uncontrolled growth and dedifferentiation results
in extremely invasive cells capable of metastasizing to distant tissues. Schematic is from
the National Institutes of Health website (http://health.nih.gov/topic/Breast/Cancer/).
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1.1.2 Breast Carcinoma Subtypes
Human breast tumours are very genotypically and phenotypically diverse (7).
Although breast cancer is a very heterogeneous disease, advances in DNA microarray
technology has allowed tumours to be classified into subtypes, based on gene expression
patterns (7). One method of classification, currently used clinically, is based on hormone
receptor status: estrogen receptor (ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER-2) (Table 1.1). Most breast cancers are luminal tumours,
accounting for 70% of all breast cancers, where cancer cells arise from the luminal lining
of the mammary ducts. These luminal breast cancers typically are positive for ER, PR
expression and negative for HER-2 overexpression, classifying them as hormone-receptor
positive cancers.

Hormone-receptor positive tumours respond well to tamoxifen, a

competitive antagonist of ER, which decreases the proliferative effects of estrogen
signaling (8). Another subtype, classified as HER-2 positive, accounts for 10-15% of all
breast tumours. HER-2 is a biomarker for breast cancer due to its ability to promote cell
proliferation in a ligand independent manner (9). HER-2 positive tumours are negative
for ER and PR expression, however, do overexpress HER-2, typically due to
amplification of its encoding gene ERBB2 (10). Monoclonal antibody treatments against
HER-2 have been developed, including Trastuzumab (Herceptin), and are used clinically
to treat and selectively target HER-2 positive tumours (11). Patients treated with these
targeted hormonal therapies such as Trastuzumab have decreased side effects and better
prognosis, when compared to patients treated with traditional chemotherapies (12).

!
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Table 1.1 Breast cancer subtypes.
Molecular Subtype

Receptor Expression

Hormone Receptor-Positive

Estrogen Receptor (ER)

(70%)

Progesterone Receptor (PR)

Examples of Targeted
Clinical Therapies
Tamoxifen

HER-2 (ERBb2)
HER-2-Positive (10-15%)

Herceptin
overexpressing

Triple Negative (15-20%)

No ER, PR or HER-2

None

1.1.3 Triple Negative Breast Cancer
Some tumours, however, do not express ER, PR nor overexpress HER-2 and are
thus defined as triple-negative breast cancers (TNBC) (Table 1.1). TNBCs account for
15-20% of all breast carcinomas. TNBC patients have a very poor prognosis, because
their tumours tend to be very aggressive, be highly metastatic, and patients display high
recurrence rates after adjuvant therapy (13). These patients, typically women under 50
years of age, lack targeted therapies and have a low 5-year survival rate (14). Studies
have shown TNBC tumours express high levels of epithelial-to-mesenchymal transition
(EMT) marker vimentin and proliferative promoting protein Ki-67 (10, 15).
Additionally, mutations in the tumour suppressor genes phosphatase and tensin homolog
(PTEN) and retinoblastoma (RB1) as well as the oncogene KRAS have been associated
with the TNBC subtype (16-18). Interestingly, TNBC expression profiles also share
similarities with breast cancers that have mutations in the DNA repair protein BRCA1,
and emerging data suggests that TNBC patients are more likely to have BRCA1 mutations
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than patients with non-TNBC (13, 19). This suggests that the loss of BRCA1 function
may play a critical role in the development of TNBC (10).
A number of studies have also associated TNBC with increased expression of the
epidermal growth factor receptor (EGFR), ranging from 41-71% (10, 20-22). EGFR,
similar to HER-2, signals via PI3K/Akt pathways in order to increase cell proliferation
and migration. A significant correlation between EGFR expression and increased tumour
grade along with distant metastasis has been shown in TNBC tumours (21). EGFR has
also been implicated as being a marker for chemotherapy response rates for TNBC
patients. Through retrospective analysis of the relationship between EGFR expression,
chemotherapy response and overall survival, for each breast cancer subtype, TNBC
patients with EGFR overexpression demonstrated the poorest chemotherapeutic response
and decreased overall survival (22). Therefore, EGFR may be a potential biomarker for
poor prognosis in TNBC patients, due to increased metastasis and lower response rates to
chemotherapies seen in patients with EGFR overexpression.
The current standard of care to treat TNBC is conventional chemotherapies
including anthracyclines, taxanes and platinum based drugs, all of which are cytotoxic
agents (23).

Although TNBC initially has a better response rate to these therapies

compared to endocrine-responsive or HER-2 positive breast carcinomas, patients have
poorer overall survival due to high recurrence rates and increased metastasis (22). Due to
the identification of upregulated molecular pathways or receptors in TNBC, including
EGFR, targeted therapies have been developed. Many of these EGFR-targeted therapies
have reached phase II clinical trials; however the results have been disappointing and
none of these therapies have been proven effective monotherapies in treating TNBC (10,

!

8!

23). Due to the current lack of targeted therapies available to patients with TNBC,
finding molecular targets that can not only be inhibited to improve patients prognosis, but
that also regulate previously characterized TNBC biomarkers would be a critical
discovery in order to improve TNBC patient care.
1.1.4 Metastatic Cascade
Metastasis is a complex process by which cancer cells break away from their
primary tumor and travel to secondary sites within the body either through the circulatory
or lymphatic system. Prognosis is extremely promising when breast carcinomas are
confined to breast tissue, as cure rates exceed 90%. However, long-term survival is
significantly decreased after metastasis occurs (24). There are currently no therapies
clinically available that specifically target metastasis (25).
In order for metastasis to occur, the tumor must undergo a number of sequential
steps, including angiogenesis, invasion of cells into surrounding tissue, intravasation,
dissemination throughout the circulatory and lymphatic systems, extravasation at distant
tissue sites and an establishment of a new tumour (26) (Figure 1.2). The initial step of
the cascade involves a subpopulation of the primary tumor acquiring a mutation to cause
a malignant phenotype. The growth and survival of these primary tumour cells depends
on the process of angiogenesis, where new blood vessels form from previous vasculature.
Once these cancer cells have acquired their own blood supply, increased genomic
instability can cause cells to lose polarity and cell-cell adhesive properties in order to gain
the ability to migrate and invade by a process called EMT. Epithelial cells that have
undergone EMT display decreased expression of adhesion molecules such as E-cadherin,
and increased expression of matrix metalloproteinases (such as MMP-2, -9, -13 and -14),
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N-cadherin, vimentin and transcription factors including Snail-Slug to acquire a
mesenchymal phenotype (26). Under normal physiological conditions, epithelial cells are
organized and polarized, and signals are conveyed by cell-cell connections accomplished
by gap and tight junctions (27). Once cells have undergone EMT, they can then invade
the underlying basement membrane, local extracellular matrix and stroma.

This is

primarily due to expression of MMPs. Next, tumor cells intravasate into blood vessels or
enter circulation through the lymphatic system. There are fewer tight junctions between
endothelial cells of the lymphatic system, compared to the cardiovascular system,
potentially making it easier for tumor cells to enter the lymphatic system (28). Once in
cardiovascular or lymphatic circulation, tumor cells must survive by evading immune
system destruction. At distant sites within the body, the cancer cells arrest in capillary
beds, bind to endothelial cells and extravasate into the surrounding tissue (29). Similar to
primary tumor growth, the secondary tumor requires angiogenesis to supply the growing
tumor. Once secondary tumors are established successful medical intervention is limited
and the lethal effects of cancer can occur.
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Figure 1.2. Schematic representation of the metastatic cascade. The initial step is the
formation of the primary tumour through increased cell proliferation (a). Cells then lose
their cell-cell adhesive properties and invade the basement membrane (b). This allows
cells to enter the circulation either via lymphatic or circulatory system (c). Some cancer
cells will survive in circulation and arrest in distant capillary beds (d). Cells will then
extravasate to secondary sites (e) and form secondary tumours (f). Adapted from Steeg et
al., (2003) (30).
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1.2 Multidrug Resistance
Multidrug resistance is a characteristic of malignant cells, which exhibit resistance
to multiple drug therapies. The development of resistance to cancer drug therapies
treatments remains a major challenge in oncology. This resistance can precede any drug
exposure (de novo), or can be acquired resistance, due to the adaptation of cells to
treatment (31). Drug resistance of cancer cells has been studied since the 1960s (32),
however, recently increased availability of sequencing technologies, including next
generation sequencing, has fostered a better understanding of the complexity of cancer
cell drug resistance.
1.2.1 Mechanisms of Drug Resistance
The best studied mechanism by which many types of cancer cells become
resistant to therapies is through the up-regulation of drug efflux transporters. These drug
efflux transporters are members of the ATP-binding cassette (ABC) transporter family,
and are able to pump out drug molecules, against their concentration gradient, to decrease
intracellular accumulation and pharmacological effects (33). There are 7 subfamilies of
these transporters, many of which are related to drug resistance (34).

Initially, P-

glycoprotein 1 (P-gp) and multidrug resistance protein 1 (MRP1), encoded by the genes
ABCB1 and ABCC1 respectively, were identified as being drug efflux proteins that
contributed to the resistance of cancer cells to conventional chemotherapeutic agents.
However, cancer cell lines devoid of these two proteins were generated that still had a
drug resistant phenotype, which lead to the further investigation and eventual
identification of breast cancer resistance protein (BCRP) and other members of the MRP
family, including multidrug resistant protein 4 (MRP4) (35). P-gp, MRP1, BCRP and
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MRP4 are highly expressed in the brain, helping form the blood-brain-barrier, as well as
in the lungs, testis and placenta. These transporters function physiologically in normal
tissues to actively pump out endogenous substances including cGMP, steroids and bile
acids, as well as function as a defense mechanism against cellular toxins. Conventional
chemotherapies, such as the anthracycline antibiotic, doxorubicin, are among the
substrates for these transporters and a link between drug efflux and drug resistance has
been established (36). Other anticancer agents that are substrates of these drug efflux
transporters include taxanes and receptor tyrosine kinase inhibitors (TKIs) (34). Many
inhibitors of these drug efflux transporters have been identified, however, their use
clinically has not been very successful (37) (Table 1.2). For example, Fumitremorgin C
(FTC), a highly specific fungal toxin to BCRP, produced severe neurotoxic effects in
mice and other mammals, preventing use clinically (38). Therefore, due to the common
decrease in chemosensitivity observed in TNBC patients, and the lack of clinical success
using drug efflux transporter inhibitors, it is critical to determine the underlying
mechanisms regulating drug resistance in order to increase the quality of patient care.
Recently, a role of microRNAs (miRNAs) has been established in the regulation
of drug resistance. These small, non-coding RNA molecules are able to bind to mRNA in
order to prevent translation and accelerate degradation (39). Although over 50 miRNAs
have been identified as having important roles in drug resistance, a number of them,
including, miR-19, miR-21, and miR-205, specifically target PTEN, implicating the
PI3K/Akt pathway as a key signaling mechanism by which drug resistance is required
(40). It is unknown whether activation of the PI3K/Akt pathway increases resistance by
directly affecting drug efflux transporter expression or by an indirect mechanism, by
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affecting cell survival signaling (40). In addition to altered miRNA expression, drugresistant cancer cells have also been shown to exhibit epigenetic changes. One of the best
examples of epigenetic alterations leading to breast cancer drug resistance is the
repression of drug efflux transport protein P-gp through hypomethylation and histone H3
lysine 9 acetylation of the P-gp promoter in MCF-7, human breast cancer cells (41).
Drug resistance can also arise from an alteration in the drug’s target, due to
mutation. An example of this occurring in lung cancer is the T790M mutation in EGFR,
which is present in half of all patients resistant to EGFR inhibitors (42). Additionally,
resistance can occur due to the non-linear, highly interconnected nature of all major
signaling pathways of the cell (43).

Due to the presence of positive and negative

feedback mechanisms as well as dynamic complex signaling, simply understanding the
protein components of a pathway is not sufficient to target its effects.

A better

understanding of the integrated signaling is required to develop cancer therapeutics with a
decreased potential for drug resistance.
Additionally, more work is required to better understand the underlying
mechanisms by which cancer cells acquire resistance in order to better predict patient
outcome and treat cancer patients more effectively.
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Table 1.2 Clinical outcomes of drug efflux transporter inhibitors. Adapted from
Videira et al. 2014 (34)
ABC
Transporter

Inhibitor

ABC Transporter
Inhibition
P-gp

P-gp

MRP

BCRP

MRP-1

Clinical Use in
Cancer

BCRP

Verapamil

X

None

LY335979

X

Phase III in leukemia

OC144-093

X

X

None

MK571

X

None

Myricetin

X

None

Sulindac

X

Phase II in leukemia

Fumitremorgin C

X

None

Ko143

X

None

1.2.2 Drug Resistance in TNBC Patients
Although drug resistance is a major obstacle when treating any subtype of breast
cancer, highly aggressive cancers, such as TNBC tumours, tend to be even more resistant
to therapies. In fact, the major cause of metastatic treatment failure in TNBC patients is
due to multidrug resistance to standard therapies (14). Treatment for TNBC patients is
limited to surgery and conventional chemotherapies, including taxanes and anthracyclines
(44). Taxanes, including paclitaxel, inhibit mitosis by stabilizing microtubules in order to
induce apoptosis (44). Anthracyclines, an example being doxorubicin, however, work by
intercalating into DNA and inhibiting topoisomerase II activity.

Predominantly,

resistance to taxanes and anthracyclines is due to decreased intracellular drug
accumulation through an increase in drug efflux via up-regulation of drug efflux

!

15!

transporter proteins (45). Due to the lack of targeted therapies available to treat TNBC,
these patients have the worst prognosis and outcome of all breast cancer subtypes (46).
Although initially having a higher response rate to chemotherapy, TNBC patients have
the lowest overall survival rate after treatment, compared to other breast cancer subtypes.
Also, these patients have shorter rates of survival after metastasis has occurred (47). This
low survival rate can be attributed to the highly adaptive response of TNBC tumours,
leading to acquired resistance to chemotherapeutics (48).

Due to the current poor

prognosis of TNBC patients, discovering new targets that can improve treatment and
reduce resistance to chemotherapy is required, as is the focus of this study.

1.3 G-Protein Coupled Receptors
G-protein coupled receptors (GPCRs) are receptors characterized by seventransmembrane α-helical domains that are able to facilitate the transduction of
extracellular signals into intracellular events. This transduction occurs via activation of
heterotrimeric G-proteins (consisting of an alpha, beta and gamma subunit) (49). The
superfamily of GPCRs is very diverse and regulates a large range of cellular responses,
specifically to many neurotransmitters and hormones (50). Due to the pivotal roles
GPCRs play in regulating healthy cell physiology, their signaling pathways are often
associated with pathogenesis.

It is estimated that 40-50% of clinically approved

therapeutics target GPCRs in a variety of diseases, including cancer, as well as metabolic
and neurodegenerative diseases (51, 52).
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1.3.1 GPCRs in Cancer
GPCRs have been implicated in the pathogenesis of cancer, by regulating cell
growth, proliferation, apoptosis and differentiation, as well as angiogenesis and
metastasis (49). Overexpression of these receptors can increase downstream signaling
leading to increased tumourigenesis, as demonstrated by endothelin receptors stimulating
angiogenesis in several cancers (53).

Additionally, some GPCRs, including the

lysophosphatidic-acid receptors in ovarian cancer, can actually increase the production of
their own ligands, leading to further activation of downstream events through an
autocrine loop (54). However, to date, very little is known about the role GPCRs play in
TNBC.
1.3.2 KISS1 and KISS1R Discovery and Expression
KISS1, originally classified as a metastasis-suppressor gene in melanoma cells,
was named in reference to its place of discovery- Hershey, Pennsylvania, home of the
famous Hershey’s Kisses (55). This original study showed that an unknown sequence,
now termed the KISS1 gene, was found only in non-metastatic neo6/C8161.1 melanoma
cells compared to metastatic C8161 cells. Additionally, when these metastatic C8161
melanoma cells were transfected with KISS1 and injected into nude immunodeficient
mice, to perform a spontaneous metastasis assay, cells transfected with KISS1 had no
effect on primary tumour growth but did significantly reduce lymph node involvement
and lung metastasis, identifying KISS1 as a potential negative regulator of metastasis
(56).
Although originally identified as having high expression in the placenta,
expression of KISS1 has also been detected in the brain, pancreas, liver, small intestine,
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heart, skeletal muscle, breast, kidneys, and lungs (57). It is now known that KISS1 is
translated into a 145 amino acid peptide, kisspeptin-145, which is subsequently cleaved
into smaller blood borne, secreted peptides, kisspeptin-54, -14, -13 and -10 (58) (Figure
1.3). These shorter kisspeptins are cleaved from the C-terminus of kisspeptin-145 by
furin, MMP-2, -9, and -14 or prohormone convertases (58). Kisspeptin-10 (KP-10) is the
shortest biologically active kisspeptin, with a sequence of YNWNSFGLRF-NH2, and this
sequence is highly conserved among vertebrates, only differing by one amino acid
substitution between human, mouse, sheep and xenopus (59).
Five years after the discovery of KISS1, three independent groups identified
kisspeptins as being ligands for the orphan GPCR, KISS1R, previously termed
H0T7T175, AXOR12 or GPR54 (60-62). By purifying kisspeptins from placenta, it was
observed that they acted as high potency agonists for KISS1R (60, 62). Similar to its
ligand, KISS1R was found to abundant in placenta, pituitary, spinal cord and pancreas,
with lower levels in other brain regions, stomach, small intestine, spleen, lung, testis,
kidney and breast (60-63).
Kisspeptins have a single high affinity binding site on KISS1R and all kisspeptins
bind with similar potencies and affinities (60, 62-64). The EC50 values being 5.47 ± 0.03
nM, 7.22 ± 0.07 nM, 4.62 ± 0.02 nM and 4.13 ± nM for KP-54, -14, -13 and -10,
respectively (60, 62, 63). Although KP-54 could potentially have more bioactivity, due to
its longer peptide sequence and resistance to enzymatic degradation and breakdown (65),
other studies have shown that all kisspeptins exhibit similar affinities (60, 62, 63). KD
values were 1.45 ± 0.1, 1.65 ± 0.15, 4.23 ± 0.1 and 2.33 ± 0.13 nM, respectively, for
kisspeptin -54, -14, -13 and -10 (60, 62, 63).
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Figure 1.3. Kisspeptins (KPs). Cleavage of kisspeptin-145 results in the production of
smaller peptides, designated KP-54, KP-14, KP-13 and KP-10.
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1.3.3 Kisspeptin/KISS1R Signaling
KISS1R is a GPCR and signals via Gαq/11 to activate primary effector
phospholipase C (PLC). PLC catalyzes the hydrolysis of phosphatidylinositol-(4,5)bisphosphate (PIP2) to form inositol-(1,4,5)-trisphosphate (IP3) and diacylglycerol
(DAG).

IP3 release into the cytoplasm causes an increase in intracellular calcium

concentration as calcium is mobilized from its internal stores; whereas DAG activates
protein kinase C (PKC) and MAP kinases extracellular signal regulated kinases (ERK1
and ERK2) (59, 66).

Additionally, Kotani and colleagues reported an increase in

arachidonic acid release upon KP-10 induced activation of KISS1R (62) (Figure 1.4).
GPCR signaling and activity can also be regulated by receptor desensitization,
internalization and degradation. Desensitization of GPCRs requires coordination from
two families of proteins: GPCR serine/threonine kinases (GRKs) and β-arrestins. Once a
GPCR binds its ligand, it adopts a conformation that allows GRKs to bind and
phosphorylate residues on the intracellular loops and carboxy terminus of the receptor.
This phosphorylation promotes β-arrestin binding which blocks all further coupling of Gproteins to the GPCR and therefore attenuating receptor signaling (50). KISS1R has been
shown to be associated with GRK2 and β-arrestin-1 and -2 in human embryonic kidney
(HEK) 293 cells (67).

Additionally, GRK2 is able to desensitize KP-10-dependent

KISS1R signaling in HEK 293 cells and β-arrestin-2 has been shown to be required for
agonist dependent KISS1R-induced ERK1/2 activation in the highly aggressive human
breast cancer cell line MDA-MB-231 (67).

β-arrestins can also target GPCRs for

internalization in clathrin-coated vesicles for endocytosis, and then the GPCRs are sorted
for destruction in the lysosome or recycling back to the cell membrane to allow further
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signaling (66). Interestingly, in HEK 293 cells, KISS1R became internalized in a KP-10dependent, as well as KP-10-indepdendent manner (67). Although KISS1R displayed a
high rate of basal internalization, the rate of KP-10-dependent internalization was
significantly greater than the basal rate (67). Furthermore, KISS1R was persistently
expressed at the membrane, even after KP-10 stimulation, and does not co-localize with
lysosomal markers, indicating ligand-induced KISS1R internalization does not result in
lysosomal degradation (68).

This dynamic recycling, as opposed to lysosomal

degradation, and KP-10-independent KISS1R internalization allows for prolonged
KISS1R signaling and indicates KISS1R may have constitutive activity (68).
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Figure 1.4 KISS1R signaling pathways. KISS1R signals via a Gαq/11-mediated
pathway, resulting in activation of phospholipase C (PLC), which leads to an increase in
phosphotidylinositol-(4,5)-bisphosphate (PIP2) causing subsequent calcium mobilization
and protein kinase C (PKC) activation. Other downstream effectors include mitogenactivated protein kinases (MAPKs), extracellular signal regulated kinases (ERK 1/2),
p38, and phosphoinositide 3-kinase (PI3K/Akt) pathways.
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1.3.4 Physiological Roles of Kisspeptin Signaling
The kisspeptin/KISS1R system plays an essential role in regulating the
reproductive axis and initiation of puberty. Kotani and colleagues first demonstrated
kisspeptin signaling as an endocrine regulator by showing intravenous administration of
kisspeptins lead to oxytocin release in rats (69). Soon after, two independent groups
revealed that patients with loss-of-function mutations in KISS1R suffer from idiopathic
hypogonadotropic hypogonadism (IHH) (70, 71). Patients with IHH have defects in adult
sexual maturation and are infertile due to the deficiency of the pituitary to secrete
gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These
patients, however, exhibit normal responsiveness when administered exogenous
gonadotropin-release hormone (GnRH), suggesting a role for KISS1R in the positive
regulation of GnRH synthesis or secretion (70). Similarly, mice deficient of KISS1R
displayed no sexual development and low circulating concentrations of gonadotropins,
implicating KISS1R as a major regulator of the neuroendocrine-reproductive axis in
humans and mice (70). Female rats injected with the KISS1R antagonist P-234 displayed
delayed pubertal onset and decreased uterine and ovarian weights at the time of expected
puberty (72). Finally, P-234 administration lead to decreased circulating levels of LH
and FSH (72). It is now clear that kisspeptins are secreted from the arcuate nucleus of the
hypothalamus and signal via KISS1R in the median eminence to cause GnRH release.
Pulsatile GnRH secretion then acts on the pituitary to synthesize and secrete FSH and LH
(73, 74). These studies clearly implicated the kisspeptin/KISS1R signaling system as a
major regulator of sexual maturity and GnRH secretion in humans as well as other
mammals.
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In addition to the role in puberty, kisspeptin signaling through KISS1R regulates

placentation. High expression of KISS1 and KISS1R mRNA has been reported in the
human placenta, suggesting a role in pregnancy (55, 60-62).

Circulating plasma

kisspeptin (KP-54) concentrations are low in non-pregnant and non-pubertal individuals
(1.31 ± 0.37 fmol/mL) (75). During the first trimester of pregnancy, circulating plasma
KP-54 concentrations are increased approximately 1000 fold (1230 ± 346 fmol/mL), and
increase a further 10000 fold (9590 ± 1640 fmol/mL) during the third trimester (69, 75).
These high kisspeptin levels drop back to non-pregnant concentrations five days post
partum, indicating the placenta might be a source for these peptides (75). In vitro assays
revealed that, KISS1 expression was decreased in first trimester trophoblast compared to
noninvasive term trophoblast, and KP-54 stimulation was able to block explant invasion
of trophoblasts by decreasing the protease activity of matrix MMP-2 (76). Along with
playing a role in trophoblast migration, kisspeptin signaling may also regulate
placentation by reducing vascularization. In a placental artery ex vivo angiogenesis
model, KP-10 significantly reduced total vessel sprouting from the placental artery (77).
1.3.5 Kisspeptin Signaling in Cancer
Lee and colleagues originally identified kisspeptins in 1996 as having antimetastatic roles in melanoma cells (55).

Since then, decreased function of the

kisspeptin/KISS1R system has been correlated with cancer progression and increased
metastasis in pancreatic (78), bladder (79), liver (80), esophageal (81), gastrointestinal
(82), ovarian (83), thyroid (84) and endometrial (85) carcinomas (reviewed, (66)). In
these cancers, KISS1 and/or KISS1R expression was found to decrease in cancer cells or
tumour tissue compared to non-malignant tissue and this was found to correlate with poor
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prognosis in patients. The anti-metastatic role of kisspeptins was first reported when it
was discovered that KISS1 gene expression was high in non-metastatic, compared to
metastatic melanoma cell lines (55). Another study demonstrated KISS1R-transfected
B16-BL6 mouse melanoma cells stimulated with kisspeptin, had increased focal
adhesions and stress fibres in vitro, and had decreased metastasized pulmonary tumour
foci when injected into the footpads of mice, compared to vehicle controls (60). To
examine the role of kisspeptin signaling in pancreatic cancers, Liang and colleagues
induced pancreatic cancer in Sprague-Dawley rats and measured KISS1 expression.
Pancreatic tumour tissue exhibited decreased KISS1 mRNA compared to adjacent
pancreatic tissue (78). Similar results were seen for bladder cancer, where loss of KISS1
expression correlates with increased cancer progression (79).

In esophageal, liver,

gastrointestinal, ovarian, thyroid and endometrial carcinomas, real-time PCR was
performed on primary tissue samples revealing that low KISS1 and KISS1R correlates
with the occurrence of aggressive tumours and poor patient prognosis (80-85).
1.3.6 Kisspeptin Signaling in Breast Cancer Metastasis
Although kisspeptin signaling has beneficial metastasis suppression activity in
many cancers, studies by our group and others have reported that the kisspeptin/KISS1R
system may have detrimental roles in breast cancer (reviewed, (66)).

Martin and

colleagues first demonstrated that KISS1 mRNA was increased in primary breast
tumours, compared to background, and KISS1 expression correlated with increased
tumour grade. KISS1R mRNA expression, however, was not significantly different
between breast tumors compared to non-malignant tissue or lymph node positive
compared to lymph node negative breast tumors (86). Additionally, KISS1 was higher in
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patients who had died from breast cancer, than those that remained healthy, suggesting
KISS1 is correlated with poor breast cancer patient prognosis (86). In vitro studies
revealed that upon insertion of KISS1 into MDA-MB-231 cells, the breast cancer cells
became more motile and invasive (86).

These results were in contrast to previous

findings of kisspeptin signaling acting as a metastasis suppressor in cancer.
KISS1 mRNA expression has been shown to be regulated by estradiol (E2), in the
rat hypothalamus (87). In breast cancer cells, Marot and colleagues showed that ERα
negatively regulated KISS1 expression (88). ERα-negative MDA-MB-231 cells were
transfected to express ERα and upon E2 treatment, KISS1 mRNA expression was shown
to decrease (88). Also, ERα-positive human breast cancer cells MCF-7 and T47D, which
endogenously express low levels of KISS1, displayed increased KISS1 expression upon
treatment with the ERα antagonist, tamoxifen, again suggesting that E2 signaling via ERα
negatively regulates KISS1 mRNA expression (88). This study also revealed that when
post-menopausal women with ERα-positive tumours were treated with tamoxifen,
patients with elevated KISS1 and KISS1R mRNA had poorest prognosis compared to
patients with low levels of KISS1 and KISS1R mRNA (88). Moreover, KISS1 mRNA
expression was found to increase with breast tumor grade (88). This study suggested that
breast tumour expression of KISS1 and KISS1R mRNA may be a marker for tumoral
resistance to anti-estrogen treatment.
The pro-metastasis role of mouse KISS1R signaling was demonstrated in vivo
using a mouse mammary tumour virus-polyoma virus middle T antigen (MMTV-PyMT)
mouse model (89).

In 2011, Cho and colleagues generated a Kiss1r haploinsufficient

MMTV-PyMT mouse model to investigate the effects of KISS1R expression on breast
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cancer establishment and metastasis.

Although Kiss1- and Kiss1r-knockout mice

displayed defective pubertal development, heterozygosity of Kiss1/Kiss1r did not result
in any sexual developmental delays, and therefore was a good model to investigate the
relationship between mouse Kiss1R signaling and breast cancer metastasis (89). In this
study, the decreased Kiss1r expression seen in the heterozygotic PyMT-Kiss1r+/− mice
attenuated breast tumor initiation, growth, latency, multiplicity and metastasis compared
to the homozygotic PyMT-Kiss1r+/+ mice (89). Additionally, primary breast cancer cells
were isolated from the PyMT-Kiss1r+/− and PyMT-Kiss1r+/+ mice and orthotopically
injected into wild-type mice to examine if primary tumour growth was affected by
decreased KISS1R expression.

Haploinsufficient PyMT-Kiss1r+/− cells displayed

decreased primary breast tumour growth. Interestingly, decreased Kiss1r expression also
correlated with a significant reduction in Mmp-9 mRNA implicating Kiss1r as a potential
regulator of breast cancer invasion (89). These findings suggest that mouse Kiss1r
signaling can regulate breast cancer initiation, progression and metastasis.
Also in 2011, studies from our laboratory demonstrated that KP-10, the shortest
biologically active kisspeptin, stimulates migration and invasion of ERα-negative human
breast cancer cells (MDA-MB-231, Hs578T, SKBR3) by transactivating EGFR (90). We
found that mechanistically KISS1R signaling stimulated MMP-9 secretion and activity
and resulted in the activation of EGFR, a β-arrestin 2 dependent pathway. Moreover, we
found that KISS1R directly binds EGFR under basal conditions, and this binding
increases upon KP-10 stimulation (90). Interestingly, we have demonstrated that the ERα
status of cells critically dictates the ability of KP-10/KISS1R to induce an invasive
phenotype. We have found that KISS1R overexpression, in ERα-negative MCF10A or
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SKBR3 human breast cancer cells, stimulated an EMT-like event, demonstrated by the
loss of E-cadherin protein expression in MCF10A cells, and increased protein expression
of N-cadherin and vimentin in SKBR3 cells. Furthermore, MCF10A and SKBR3 cells
overexpressing KISS1R displayed increased cell invasiveness (91). Interestingly, KP-10
failed to transactivate EGFR or stimulate invasion in ERα-positive MCF7 or T47D breast
cancer cells (91) (Figure 1.5).

We found that ERα negatively regulated KISS1R

expression and function (91). Overexpression of KISS1R in SKBR3 cells also induced
extravasation using the chick cholioallantoic membrane (CAM) assay (91). Interestingly,
KP-10 does not activate other members of the EGFR family, such as HER-2 (unpublished
data). Lastly, we found that IQGAP, an actin-binding scaffold protein, was discovered to
be a binding partner of KISS1R and both proteins localized at the leading edge of
migrating cancer cells (91).

Although the role of KISS1R in cancer cell invasion,

migration and metastasis has been investigated, to date, it is unknown whether the
kisspeptin/KISS1R system regulates breast cancer drug resistance, and thus is the focus
of this thesis.
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Figure 1.5. Kisspeptin/KISS1R signaling system in breast cancer. KISS1R signaling
can lead to epidermal growth factor (EGFR) activation via β-arrestin 2-dependent
pathway.

Kisspeptin/KISS1R signaling can stimulate epithelial to mesenchymal

transition (EMT), and increase matrix metalloporteinases-9 (MMP-9) expression and
activity, to stimulate breast cancer cell invasion.
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1.4 EGFR Signaling in Breast Cancer
EGFR (ErbB1) is a member of the EGF receptor family of receptor tyrosine
kinases, other members include: HER-2 (ErbB2), HER-3 (ErbB3) and HER-4 (ErbB4).
These receptors consist of an extracellular ligand binding domain, a single hydrophobic
transmembrane domain and an intracellular domain with protein kinase activity (92).
Members of the EGF receptor family are ubiquitously expressed in epithelial,
mesenchymal and neuronal cells and control many important cellular functions including
proliferation, survival, motility and differentiation (93). Physiological activation of these
receptors includes ligand binding which triggers homo- or heterodimerization of EGFR
with another ErbB receptor family member, most commonly HER-2. This dimerization
leads to autophosphorylation of tyrosine residues on the intracellular domain, allowing
for interactions to be made with downstream molecules and initiation of signal
transduction (94).
While EGFR signaling is essential for many normal cellular processes, atypical
activity of the receptor has been shown to promote tumourigenesis (93). In fact, EGFR
was the first receptor studied demonstrating that receptor overexpression can lead to
cancer (95). In cancer, EGFR is a key regulator of cell proliferation, tumorigenesis, and
is an essential driving force for the aggressive growth behaviour of cancer cells (96).
EGFR is essential for normal breast development, as mice with EGFR mutations
had impaired mammary gland development (97). Interestingly, EGFR is frequently
overexpressed in highly aggressive TNBCs (10, 20-22). Increased EGFR expression was
also found in patients with metastasis, compared to those without (98). Due to the
overexpression of EGFR in TNBCs, EGFR has been a primary target in TNBCs. Current
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anti-EGFR therapeutics consist of small molecule tyrosine kinase inhibitors (TKI), that
compete with ATP to bind to the intracellular catalytic domain of EGFR, and anti-EGFR
monoclonal antibodies, which bind extracellularly and prevent receptor activation (99).
Unfortunately, limited clinical success has been seen in TNBC patients given EGFRtargeted monotherapies, where acquired tumour drug resistance is a major obstacle.
Greater efficacy, however, has been seen when TNBC patients were treated with antiEGFR therapies in combination with traditional chemotherapies, including cisplatin and
carboplatin (100).
EGFR signaling also regulates cell survival and is thought to induce tumour drug
resistance (101). Although the role of EGFR in modulating chemosensitivity has been
debated, the majority of reports show significant growth inhibition and/or
chemosensitivity upon EGFR-blockage through TKIs and monoclonal antibodies (101).
Additionally, EGFR has been shown to have key functional interactions with other RTKs
(102). For example, the RTK, AXL, is able to bind EGFR and become transactivated
following EGFR activation, independent of stimulation by the AXL ligand (103). This
crosstalk between EGFR and AXL has been shown to regulate oncogenic signaling and
even promote resistance to targeted therapies, specifically to anti-EGFR therapies in nonsmall cell lung cancer and breast cancer (103, 104). Since we have shown that KISS1R
can transactivate EGFR, the proposed work investigates if this signaling pathway induces
drug resistance to cytotoxic agents in TNBC cells as well.
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1.5 TAM Family of Receptor Tyrosine Kinases
The TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases share
similar overall structure and function (105). TAM RTKs are frequently overexpressed in
numerous cancers where they promote cell survival and allow for tumour cell growth
(106). Little is currently understood about TYRO3 signaling, however, MER and AXL
have been shown to activate standard proliferative pathways with in the cell, including
the PI3K/Akt and MAPK/ERK pathways. This activation of proliferative signaling,
however, typically promotes cell survival, as opposed to cell proliferation (106).
1.5.1 AXL Signaling in Cancer
AXL was originally detected in 1998 from two patients with chronic
myelogenous leukemias. Overexpression of AXL has been reported in several human
cancers including breast, colon, esophageal, thyroid, ovarian, gastric, renal, glioma and
lung (107, 108). The oncogenic potential of AXL is due to its tyrosine kinase domain,
which can be activated independent of ligand binding through overexpression, or by
binding of its ligand, growth arrest-specific gene 6 (Gas-6) (109). Using a xenograft
orthotopic breast tumour model, primary tumour growth was decreased when MDA-MB231 had decreased AXL expression due to RNAi knock down (110). Similar results were
found in vitro, when RNAi specific knockdown of AXL decreased breast cancer cell
invasion (111). Since then, it has been discovered that AXL signals via downstream
phosphorylation of Akt and ERK1/2 in order to protect cells from apoptosis, as well as
increase migration and growth (111). Inhibition of AXL can block Akt/ERK pathways,
however, complete inactivation of AXL requires simultaneous inhibition of other receptor
tyrosine kinases, including EGFR, indicating a crosstalk between EGFR and AXL (103).
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Specifically, it has been shown that EGFR transactivation of AXL in TNBC cells can
lead to increased downstream signaling, inducing a invasive phenotype, one that is not
primarily activated by EGFR itself (108). Recent studies have reported that AXL may
also promote drug resistance in a number of cancers. Overexpression of AXL has been
linked to imatinib resistance, a TKI, in gastrointestinal stromal tumours (112). AXL
overexpression has been associated with resistance to conventional chemotherapies as
well as targeted therapies in a number of other cancers, including acute myeloid
leukemia, lung, ovarian, and breast (113-115).
1.5.2 AXL and Breast Cancer Drug Resistance
The role that AXL plays in breast cancer drug resistance is currently under
investigation. Thus far, in TNBC, AXL has been specifically linked to resistance of
EGFR-targeted therapies (116).

Additionally, shRNA-mediated depletion of MER,

another member of the TAM receptor tyrosine kinase family, resulted in a reduction of
prosurvival proteins known to play roles in chemoresistance, including survivin (114).
Another study found that chronic exposure of breast cancer cells, which endogenously do
not express AXL, to lapatinib, a TKI currently being used clinically to treat breast
tumours, caused lapatinib resistance as well as de novo AXL expression. Surprisingly,
upon AXL depletion via AXL-targeted siRNA, sensitivity to lapatinib was restored (117).
Interestingly, in TNBC MDA-MB-231 cells, EGFR has been shown to
transactivate AXL, in a Gas-6-independent manner (103). This transactivation could
potentially lead to a diversified downstream signaling cascade that is beyond that
produced by EGFR activation and signaling alone (103). Additionally in TNBC cells,
AXL and EGFR are overexpressed, and through immunoprepiciptation experiments, the
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two receptors have been shown to physically interact (103).

A similar study

demonstrated that EGFR activation, upon EGF stimulation in MDA-MB-231 cells, led to
phosphorylation of AXL; however, EGFR was not phosphorylated when AXL was
stimulated by Gas-6 (118). Recently, AXL has also been shown to stimulate EMT in
breast cancer cells, and EMT has been shown to correlate with acquired resistance in
many cancers (108, 118). Depletion of AXL, through shRNA, was shown to decrease
markers of EMT, including vimentin and Snail-Slug in breast cancer cells (118).
Similarly, cells treated with an AXL inhibitor, reversed the EMT phenotype and became
more sensitive to paclitaxel (118).
Since AXL has been implicated in regulating breast cancer metastasis as well as
drug resistance, the discovery and targeting of upstream regulators of AXL would
potentially decrease two of the current major problems with treating TNBC. Whether
KISS1R signaling activates AXL to induce drug resistance is unknown and will be
investigated here.
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1.6 Rationale, Objectives and Hypothesis
1.6.1 Rationale
KISS1 expression increases in human tumour tissue compared to healthy
mammary tissue and this increase correlates positively with an increase in breast tumour
grade (86). Additionally, breast cancer patients with high KISS1 and KISS1R mRNA
were associated with shortest relapse-free survival (88). Our laboratory has previously
shown that KISS1R signaling stimulates ERα-negative breast cancer cell invasion and
migration by transactivating EGFR (90). However, whether KISS1R regulates EGFR
expression and if this signaling pathway regulates drug resistance in ERα-negative breast
cancer cells is unknown and will be investigated here.

1.6.2 Hypothesis
In ERα-negative human breast cancer cells, KISS1R signaling promotes EGFR
expression and drug resistance.

1.6.3 Objectives
To determine whether:
1) In ERα-negative breast cancer cells KISS1R signaling induces EGFR expression
2) KISS1R signaling stimulates breast cancer drug resistance and to identify the
underlying mechanisms by which this occurs
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2.1 Materials and Methods

Human Cell Culture: All human breast cancer cells were purchased from ATTC
(Manassas, VA).

Characteristics of cell lines are shown in Table 2.1. Cells were

maintained at 37 ˚C with 5% CO2. MCF10A cells were grown in mammary epithelial
basal medium (MEBM; Clonetics-Cambrex, Walkersville, MD) supplemented with a
MEGM Single Quots kit (bovine pituitary extract, human epidermal growth factor,
insulin, hydrocortisone, gentamicin/amphotericin) and cholera toxin (100 ng/mL).
SKBR3 and MDA-MB-231 were cultured in Rosswell Park Memorial Institute 1640
(RPMI 1640) (Invitrogen, Burlington, ON) supplemented with 10% (v/v) fetal bovine
serum (FBS) (Sigma-Aldrich, Oakville, ON). All stable cell lines generated (MCF10A
FLAGKISS1R and SKBR3 FLAGKISS1R) represent polyclonal cell populations as
described (1).
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Table 2.1. Summary of the human cell culture models used in the study.

Cell Lines

Characteristics of the Parental Cell Line
Human Mammary Epithelial Cells

MCF10A
Derivatives:
! MCF10A pFLAG
! MCF10A FLAGKISS1R (1)

!

Non-malignant mammary epithelial cells isolated
from patient with fibrocystic disease (2)

!

Non-motile and non-invasive (2)

!

ERα-negative (3)

!

Endogenously express KISS1R (1)

!

Overexpression of KISS1R stimulates EMT-like
phenotype and cell invasion (1)

Human Breast Cancer Cells

SKBR3
Derivatives:
! SKBR3 pFLAG
! SKBR3 FLAGKISS1R (1)

MDA-MB-231

!

Weakly invasive, isolated from pleural effusion of
patient (4)

!

ERα-negative (5)

!

HER-2 overexpressing breast adenocarcinoma (5)

!

Very low endogenous expression of KISS1R (1)

!

Overexpression of KISS1R stimulated
mesenchymal marker expression and tumour cell
extravasation in vivo (1)

!

Highly invasive breast adenocarcinoma (6)

!

ERα-negative (6)

!

Express KISS1R endogenously (7)
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Stable Transfections: FLAGKISS1R and pFLAG (vector control) constructs were
generated as described (8) and obtained from Dr. Andy Babwah. MCF10A and SKBR3
cells (1 X 106 cells) were transfected with 5 µg cDNA constructs by microporation
(1700V, 10 pulse width, 3#) using the NeonTM Transfection System (Invitrogen)
according to the manufacturer’s instructions.

A heterogeneous population of stable

transfectants was selected by using media containing 750 µg/mL G418 (Invitrogen) as
described (1).

Stable heterogeneous populations of cells were maintained in media

containing G418 (1.5 ng/mL) and expression of proteins was verified weekly by Western
blot analysis.

Immunofluorescence Microscopy: SKBR3 cells expressing pFLAG or FLAGKISS1R
were immunostained as previously described (1, 9). Briefly, SKBR3 cells were washed
with Hank’s Balanced Salt Solution (HBSS), fixed and permeabilized with 4%
paraformaldehyde (0.2% Triton-X) at room temperature for 20 minutes.

Phalloidin

(1:100, Invitrogen) conjugated to Alexa Fluor 555 was incubated for 1 hour to visualize
F-actin stress fibers. Nuclei were stained with 0.01% Hoechst 33258 (Invitrogen) or
Sytox Green (Invitrogen). Images were acquired using an LSM-510 META laserscanning microscope (Zeiss, Oberkochen, Germany).

Immunoblot Assays: Experiments were performed as previously described (1, 9).
MCF10A, SKBR3 and MDA-MB-231 cells were lysed using RIPA buffer (150 mM
NaCl, 50 mM Tris pH8, 5 mM EDTA, 1% NP40, 0.1% SDS, 10 mM NaF, 0.5%
deoxycholate, 10 mM sodium pyrophosphate, protease inhibitors). Protein (50 µg or 100
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µg) was separated by SDS-PAGE and expression was examined using antibodies raised
against human proteins: rabbit anti-KISS1R (1:2000, Abcam, Toronto, ON), mouse antiBCRP (1:150, Abcam), mouse anti-MRP1 (1:750, Abcam), rat anti-MRP4 (1:1000,
Abcam), rabbit anti-AXL (1:1000, Cell Signaling, Whitby, ON), rabbit anti-Snail-Slug
(1:500, Santa Cruz, Dallas, TX), rabbit anti-vimentin (1:500, Cell Signaling), rabbit antiERK (1:1000, Cell Signaling), rabbit anti-phoshpo-ERK1/2 (1:2000, Cell Signaling),
rabbit anti-Akt (1:1000, Abcam), rabbit anti-phospho-Akt (1:1000, Abcam), rabbit antisurvivin (1:1000, ThermoScientific, Burlington, ON), rabbit anti-SP-1 (1:1000, Millipore,
Billurica, MA) or rabbit anti-NF-κB (1:1000, Millipore). Rabbit (1:2500, GE Healthcare
UK, Buckinghamshire, UK), mouse (1:2500, GE Healthcare UK) and rat (1:10000,
Invitrogen) secondary antibodies conjugated to horseradish peroxidase were used to
visualize chemiluminescence. β-actin (anti-rabbit polyclonal, 1:2000, Sigma-Aldrich)
expression was used as a loading control.

Scratch Assays for Cell Motility: SKBR3 cells expressing pFLAG or FLAGKISS1R
were seeded into a 12-well dish in RPMI and grown to 100% confluence. Cells were
then serum starved, grown in media without FBS, for 24-hours and scratched with a
sterile pipette tip before being left in serum free media or FBS supplemented media as
previously described (1, 9). Cells were allowed to migrate into the scratch for 24 hours.
Cells were imaged every 15 minutes using an automated Olympus IX-81 microscope.
Distance travelled was measured at seven random locations per well, and wells were
analyzed in duplicates. This analysis was performed using ImagePro software (Media
Cybernetics, Rockville, MD).
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Doxorubicin Accumulation Assay: SKBR3 pFLAG and SKBR3 FLAGKISS1R cells
were treated with 1 µM of doxorubicin for 2 hours as previously described (10). Cells
were then fixed with 4% paraformaldehyde at room temperature for 20 minutes and
washed with HBSS. Nuclei were then stained with 0.01% Hoechst 33258 (Invitrogen).
Cells were mounted on slides and imaged using an LSM-510 META laser scanning
microscope using a Zeiss 63X objective, oil immersion lens.

MTT Cell Viability Assay: MTT cell viability assays were conducted as previously
described (11) and according to manufacturer’s instruction (Cell Signaling). Briefly, 7.5
x 104 cells (MCF10A pFLAG, MCF10A FLAGKISS1R, SKBR3 pFLAG, SKBR3
FLAGKISS1R and MDA-MB-231) were plated in a 96-well plate and stimulated with 1
µM P-234 or left untreated overnight in media containing 10% FBS. Prior to doxorubicin
treatment, cells were pretreated for 10 minutes with 50 µM MK-571, or a cocktail of drug
efflux transporter inhibitors (50 µM MK-571, 10 µM FTC, 1 µM LY-335979), to inhibit
MRPs, BCRP and P-gp, respectively, or with vehicle control.

A dose response

experiment was conducted, using graded concentrations of doxorubicin, ranging from
0.01 µM to 300 µM, for MCF10A and SKBR3 cells or 0.01 µM to 2 mM, for MDA-MB231 cells, for 48 hours. Erlotinib experiments were performed by treating cells for 72
hours with graded concentrations, ranging from 0.1 µM to 150 µM. Media was then
aspirated and cells were incubated with 0.5 mg/mL of MTT labeling (3-(4,5dimethylthiazol-2-yl)-2,5-diephenyltetrazolium bromide) agent for 4 h and subsequently
solubilized with DMSO. Absorbance of the supernatant was read at 550 nm with a
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background subtraction at 670 nm, using a Victor3V 1420 Multi Label Counter (Perkin
Elmer, Waltham, MA).

Cell Growth Assays: To determine cell growth, monolayer cultures of SKBR3 pFLAG
and SKBR3 FLAGKISS1R cells (5 X 105), were seeded into 60-mm dishes and
trypsinized at 24, 48 and 72 hours.

The number of cells was determined using a

hemocytometer as previously described (1, 9).

AXL Depletion by siRNA: SKBR3 FLAGKISS1R cells were grown to 60% confluency
and transfected with 4 µg of control or AXL siRNA (Ambion, Life Technologies, Austin,
TX) by jetPRIME reagent, according to manufacture’s instructions (Polyplus
Transfection, Illkirch, France).

Cells were maintained in FBS supplemented media

without antibiotics for 48 hours. Protein expression of AXL in SKBR3 FLAGKISS1R
cells was determined by Western blot analysis.

EGFR Immunoprecipitation: These experiments were conducted as previously
described (1, 9). SKBR3 pFLAG and SKBR3 FLAGKISS1R cells were cultured to 80%
confluency and serum-starved for 24 hours. Cells were washed with ice-cold phosphatebuffered saline (PBS) and lysed in glycerol lysis buffer (20 mM HEPES, 150 mM NaCl,
1.5 mM MgCl2, 1 mM EDTA, 2 mM Na3VO4, 1 mM NaF, 10% glycerol, 1% Triton X100) containing protease inhibitors (1 µL/mL aprotinin, 1 µL/mL leupeptin and 10
µL/mL AEBSF). Lysates (500 µg of total protein) was used for immunoprecipitation
studies. EGFR was immunoprecipitated from total lysates using anti-EGFR antibody (4
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µg, Millipore), incubated at 4 °C overnight. Immunoprecipitated proteins were then
pulled-down with protein G Dynabeads (Life Technologies) and resolved by Western blot
analysis. Phosphorylated EGFR was determined using an antiphosphotyrosine antibody
(PY-20, Santa Cruz) at 1:1000.

Total EGFR was determined using an anti-EGFR

antibody (1:4000, Millipore). Densitometric analysis was performed using VersaDoc
Imaging System (Bio-Rad, Hercules, CA).

Quantitative Reverse Transcription PCR: Total RNA was extracted from SKBR3
pFLAG, SKBR3 FLAGKISS1R, or MDA-MB-231 cells using RNeasy Mini Kit
instructions (Qiagen, Venlo, Netherlands) and quantified spectrophotometrically at
260nm. Total RNA (1 µg) was used to prepare cDNA. Reverse-transcription was carried
out according to manufacturer’s instructions using iScript RT Supermix (Bio-Rad). To
investigate the expression of KISS-1, KISS1R, EGFR, AXL, BCRP, MRP1, MRP4 or
control (GAPDH), real-time quantitative polymerase chain reaction (RT-qPCR) was
performed using SYBR green methodology. Standard curves for each gene were
constructed separately using serially diluted reverse-transcription products. The mRNA
levels of each gene of interest were determined by amplification of 25 ng of cDNA using
specific primers (Table 2.2), RNase-free water, and SsoFast EvaGreen Supermix (BioRad). Results were normalized to GAPDH. RT-qPCR runs were comprised of an initial
denaturation step, 95°C for 3 min, then 40 cycles at 95 °C for 10 s, and 60 °C for 30 s.
Experiments were performed in triplicates for each data point.
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Chromatin immunoprecipitation (ChIP): ChIP was performed on SKBR3 pFLAG and
SKBR3 FLAGKISS1R cells using EZ-Magna ChIPTM G-Chromatin Immunoprecipitation
Kit (Millipore) according to the manufacturer’s protocol, with slight modifications.
Briefly, DNA was cross-linked to protein by treating SKBR3 cells with 1% formaldehyde
for 20 minutes at room temperature. Unreacted formaldehyde was then quenched with
137.5 mM glycine for 5 minutes at room temperature.

Cells were then lysed and

sonicated to shear DNA to a length of 200 to 1,000 base pairs. Chromatin samples were
then incubated overnight at 4 °C with antibodies to SP-1 (4 µg/sample, Millipore), RNA
polymerase II (RNA Pol II, 2 µg/sample, Millipore) or nonimmune IgG from the same
host species (anti-rabbit or anti-mouse, Millipore) as well as 20 µL protein G magnetic
beads. After overnight incubation, beads were washed, crosslinks were reversed and
chromatin was eluted with 2-hour Elution Buffer and Proteinase K treatment. DNA was
subsequently purified using spin columns. The binding of SP-1 (-101 to - 88) and RNA
Pol II to the human EGFR promoter (12) was quantified by RT-qPCR using primers that
amplified -129 to -23 (Table 2.2).
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Table 2.2. Summary of the RT-qPCR primers used in this study.

Gene

Primer Sequence

KISS1

F
R

5’-GGACCTGCCTCTTCTCACCA-3’
5’-ATTCTAGCTGCTGGCCTGTG-3’

KISS1R

F
R

5’-CCCACCCTCTGGACATTCAC-3’
5’CCTAGAAGTGCCTTGAGGCTTG-3’

AXL

F
R

5’-CAGCAAGAGCGATGTGTGGT-3’
5’-CGATTTCCCTGGCGCAGATA-3’

EGFR

F
R

5’-CAACAGCACATTCGACAGCC-3’
5’-CTCCGTGGTCATCGTCCAAT-3’

MRP1

F
R

5’-CGGAAACCATCCACGACCCTATTC-3’
5’-ACCTCCTCATTCGCATCCACCTTG-3’

MRP4

F
R

5’-AAGTGAACAACCTCCAGTTCCAG-3’
5’-GGCTCTCCAGAGCACCATCT-3’

F
R
F
R
F
R

5’-TGGCTGTCATGGCTTCAGTA-3’
5’-GCCACGTGATTCTTCCACAA-3’
5’-TGGTATCGTGGAAGGACTCA-3’
5’-TTCAGCTCAGGGATGACCTT-3’
5’-GACAGGCCACCTCGTCG-3’
5’-CCGGCTCTCCCGATCAATAC-3’

BCRP
GAPDH
SP-1
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Subcellular Fractionation: SKBR3 pFLAG and SKBR3 FLAGKISS1R cells were
washed with PBS and lysed in RIPA buffer supplemented with protease inhibitors.
Lysed cells were then pelleted by centrifugation.

Supernatant was collected as the

cytosolic fraction. The pellet was then washed with ice-cold PBS and resuspended in
RIPA buffer. The resuspended pellet was then sonicated on ice and centrifuged to
remove any unsolubilized cellular contents. Total protein was acquired by lysing SKBR3
cells in RIPA buffer, and sonicating, on ice, the total lysate. Sonicated lysates were then
centrifuged at 15,000 g for 20 minutes at 4 ºC, to remove unsolubilized cellular contents.
Aliquots of cytoplasmic, nuclear and total extracts (50 µg) were used as samples for
Western immunoblot analysis.

Statistical Analysis: One-way analysis of variance (ANOVA) with a Dunnett’s post-hoc
test or two-way ANOVA followed by Bonferonni post-hoc test was performed using
GraphPad Prism 5 (GraphPad Software, Inc). Differences were considered statistically
significant at p<0.05.

2.2 Results
KISS1R overexpression increased mesenchymal phenotype of SKBR3 breast cancer
cells
The process of EMT has been shown to be critical in the progression of many
cancers, including breast (13). Switching of the cellular phenotype from epithelial to
mesenchymal requires numerous modifications including a decrease of cell adhesion,
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morphological changes from cobblestone (epithelial) to spindle (mesenchymal) shape and
the acquisition of a migratory and invasive phenotype (13). A defining feature of EMT is
a loss of E-cadherin, and an increase in expression of mesenchymal cell markers
including vimentin, N-cadherin and Snail-Slug (14).
To evaluate the role of KISS1R in breast cancer, we took a gain-of-function
approach by overexpressing KISS1R in the weakly invasive SKBR3 cells, which
endogenously express very low levels of KISS1R (1) (Figure 2.1A). FLAGKISS1R and
pFLAG (vector control) were stably expressed in SKBR3 cells; these cells represent
heterogeneous populations of transfectants and have been previously characterized (1).
SKBR3 FLAGKISS1R cells have increased expression of mesenchymal markers,
vimentin and N-cadherin, and extravasate in chick embryo chorioallantoic membrane
(CAM) assays, compared to vector controls (1).
Western blot analysis of EMT markers in SKBR3 FLAGKISS1R cells verified
our previous findings that there was an increase in expression of the mesenchymal
markers vimentin, N-cadherin and Snail-Slug compared to vector controls (Figure 2.1A).
Similarly, overexpression of KISS1R increased the mesenchymal phenotype of SKBR3
cells resulting in more spindle shaped morphology, compared to the vector control
(Figure 2.1B).

SKBR3 FLAGKISS1R cells also had increased actin stress fiber

formation, often associated with cellular migration (Figure 2.1C). This data suggests, as
we’ve already demonstrated (1), that the stable expression of KISS1R in ER-negative
SKBR3 cells induces a partial EMT-like phenotype.
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A

B

C

Figure 2.1. KISS1R overexpression increased the mesenchymal phenotype of
SKBR3 breast cancer cells. A) Representative Western blots showing expression levels
of KISS1R (n=6) and mesenchymal markers vimentin (n=3), N-cadherin (n=3), and
Snail-Slug (n=3) in SKBR3 pFLAG and SKBR3 FLAGKISS1R cells. Western blot
analysis performed with rabbit anti-KISS1R, rabbit anti-vimentin, mouse anti-Ncadherin, and rabbit anti-Snail-Slug. Densitometric analysis of Western blot expression
normalized to β-actin. Student’s unpaired T-test: *, P<0.05. Columns represent mean
protein expression ± SEM. B) Representative DIC images of SKBR3 pFLAG (control) or
SKBR3 FLAGKISS1R (n=3). 40x. Scale Bar, 50µm. C) F-actin stained with phalloidinAlexa Fluor 555 (red) and nuclei using Sytox Green (green) and visualized by confocal
microscopy. Images representative of four independent experiments. Scale Bar, 20µm.
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KISS1R overexpression increased KISS1 mRNA expression in SKBR3 cells
KISS1 is the gene encoding for kisspeptin peptides, the ligands for KISS1R (15).
RT-qPCR was performed in order to determine expression of KISS1R and KISS1 mRNA
in SKBR3 pFLAG and SKBR3 FLAGKISS1R cells. SKBR3 FLAGKISS1R cells had
significantly increased KISS1R mRNA and protein expression, compared to pFLAG
controls (Figure 2.2).

Interestingly, SKBR3 FLAGKISS1R cells also expressed

increased KISS1 mRNA (Figure 2.2). This data suggests that KISS1R overexpression
appears to increase the expression of the gene encoding its own ligand, which may
promote KISS1R signaling to increase breast cancer progression.
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Figure 2.2. KISS1R overexpression increased KISS1 mRNA in SKBR3 cells.
Relative mRNA expression of KISS1R and KISS1 as identified by RT-qPCR (n=4).
Student’s unpaired T-test: *, P<0.05. Columns represent mean relative mRNA
expression, normalized to GAPDH ± SEM.
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KISS1R signaling stimulated motility of breast cancer cells.
Cells that have undergone EMT display enhanced motility (1), a critical process in
cancer metastasis.

In order to assess if KISS1R expression regulated SKBR3 cell

motility, scratch assays were performed, as previously described (1, 9). SKBR3
FLAGKISS1R cells migrated further in comparison to vector control cells (Figure 2.3A).
To exclude confounding effects of KISS1R overexpression on cell proliferation, cell
growth assays were performed to determine the doubling time of these cells. Both
SKBR3 pFLAG and SKBR3 FLAGKISS1R cells had a doubling time greater than 48
hours (Figure 2.3B). Thus, this suggests that the effects of KISS1R overexpression on
scratch closure was due to the increased cell motility and not because of increased
cellular proliferation.
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A

B

Figure 2.3. Overexpression of KISS1R increased breast cancer cell motility. A)
KISS1R overexpression in SKBR3 cells increases the distance closed by FLAGKISS1R
cells compared to pFLAG controls over a 24 hour period (n=3). Cells were allowed to
migrate in serum-free (SF) or fetal bovine serum (FBS)- supplemented media. Two-way
ANOVA followed by Bonferroni post-hoc test: a, P<0.05 for pFLAG FBS vs
FLAGKISS1R FBS; b, P<0.05 for FLAGKISS1R SF vs FLAGKISS1R FBS; c, P<0.05
for FLAGKISS1R SF vs pFLAG SF. Scale Bar, 100µm. B) SKBR3 pFLAG and SKBR3
FLAGKISS1R cells were cultured for 72 hours with or without 100 nM KP-10 and
counted at 24 hour intervals (n=3). Two-way ANOVA followed by Bonferroni post-hoc
test: a, P<0.05 for pFLAG compared to FLAGKISS1R; b, P<0.05 for pFLAG+KP10
when compared to FLAGKISS1R+KP10.
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KISS1R signaling increased endogenous EGFR protein and mRNA expression
Previously, we have demonstrated that KISS1R promotes the invasion of ERαnegative breast cancer cells, MDA-MB-231 and Hs578T, by activating EGFR (1, 9). We
next sought to determine if KISS1R regulates EGFR expression in KISS1R
overexpressing cells. Thus, EGFR protein and mRNA expression was examined in
SKBR3 cells overexpressing KISS1R. SKBR3 FLAGKISS1R cells had in an increase in
total endogenous EGFR protein, although the relative amount of active EGFR did not
appear to increase with KISS1R overexpression, compared to pFLAG control cells
(Figure 2.4A). EGFR mRNA expression also increased in SKBR3 FLAGKISS1R cells
compared to SKBR3 pFLAG cells. Interestingly, in SKBR3 FLAGKISS1R as well as
MDA-MB-231 cells, EGFR mRNA expression decreased upon treatment of cells with
KISS1R antagonist, P-234 (Figure 2.4B-C). Therefore, this data suggests that KISS1R
signaling regulates EGFR transcription.
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A

B

C

Figure 2.4. KISS1R overexpression and signaling increased endogenous EGFR
expression. A) Representative Western blots showing overexpression of KISS1R in
SKBR3 breast cancer cells resulted in increased endogenous EGFR expression (n=6).
Phosphorylated (active) EGFR (PY20) was also examined in pFLAG and FLAGKISS1R
cells (n=3). Densitometric analysis of Western blot expression was normalized to βactin. B) EGFR mRNA in SKBR3 pFLAG and FLAGKISS1R cells analyzed by RTqPCR. SKBR3 pFLAG and FLAGKISS1R cells were serum-starved for 48 hours with
the presence of 1 µM P-234 or 20% acetonitrile vehicle control (VEH) (n=3). Two-way
ANOVA followed by Bonferroni post-hoc test: a, P<0.05 for pFLAG VEH vs
FLAGKISS1R VEH; b, P<0.05 for FLAGKISS1R VEH vs FLAGKISS1R P-234; c,
P<0.05 for FLAGKISS1R P-234 vs pFLAG P-234. C) EGFR mRNA in MDA-MB-231
cells. Cells were serum-starved for 48 hours in the presence of 1 µM P-234 or vehicle
control. Total RNA was isolated and RT-qPCR was performed using primers for EGFR
and GAPDH (n=3). One-way ANOVA followed by Dunnet’s multiple comparison test;
*, P<0.05. Columns represent mean relative mRNA expression, normalized to GAPD ±
SEM.
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KISS1R overexpression increased nuclear expression of SP-1 and NF-κB
To better understand how KISS1R signaling increases EGFR mRNA and protein
expression, subcellular fractionation was performed in SKBR3 pFLAG and SKBR3
FLAGKISS1R cells. The location and expression of the transcription factors SP-1 and
NF-κB, both of which are known to positively regulate EGFR expression, was examined
(16, 17).

There was an enrichment of SP-1 in the nuclear fraction of SKBR3

FLAGKISS1R cells compared to pFLAG control cells, as demonstrated by Western blot
analysis (Figure 2.5A). Similarly, NF-κB expression in the nuclear fraction was also
increased upon in SKBR3 FLAGKISS1R cells (Figure 2.5B). Histone H3 and HSP90
were used nuclear and cytosolic markers, respectively (18, 19). This data suggests that
KISS1R may regulate EGFR transcription via transcription factors SP-1 and NF-κB.
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Figure 2.5. KISS1R overexpression increased nuclear expression of SP-1 and NF-κB
in SKBR3 breast cancer cells. Western blot showing overexpression of KISS1R in
SKBR3 cells increases expression of (A) SP-1 and (B) NF-κB in the nuclear fraction.
Protein was isolated from cytosolic and nuclear fractions from SKBR3 pFLAG and
SKBR3 FLAGKISS1R cells. Western blot analysis performed with anti-human rabbit
anti-SP-1 and mouse anti-NF-κB. Mouse anti-Histone H3 and rabbit anti-HSP90 were
used as nuclear and cytosolic markers, respectively. Densitometric analysis of Western
blot expression normalized to Histone H3 (n=3). Student’s unpaired T-test: *, P<0.05.
Columns represent mean protein expression ± SEM.
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KISS1R overexpression increased nuclear recruitment of SP-1 to the EGFR promoter
To determine if increased SP-1 nuclear expression was a potential mechanism by
which KISS1R signaling up-regulates EGFR expression, we performed chromatin
immunoprecipitation (ChIP) on SKBR3 pFLAG and SKBR3 FLAGKISS1R cells.
Binding of SP-1 to the EGFR promoter was significantly increased 2-fold in
FLAGKISS1R cells compared to pFLAG control cells (Figure 2.6A). Recruitment of
RNA Pol II to the EGFR promoter was also increased 2-fold (Figure 2.6B). This data
suggests that increased EGFR expression in SKBR3 FLAGKISS1R cells may be due to
increased nuclear protein expression of SP-1 and also binding of SP-1 to the EGFR
promoter.
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A

B

Figure 2.6. KISS1R overexpression increased SP-1 and RNA Pol II recruitment to
the EGFR promoter. A) SP-1 binding and B) RNA Pol II binding to the EGFR
promoter, to the most proximal of SP-1 binding sites to the transcriptional start site.
ChIP was performed on SKBR3 pFLAG and SKBR3 FLAGKISS1R cells using an anti
SP-1-specific or RNA Pol II-specific antibody. Relative binding of SP-1 or RNA Pol II
is expressed as a percentage of pFLAG control binding. SKBR3 pFLAG control cells
were arbitrarily defined as 100% (n=3). One-way ANOVA followed by Dunnet’s
multiple comparison test: *, P<0.05 . Columns represent mean relative SP-1 or RNA Pol
II binding ± SEM.
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KISS1R overexpression inhibited doxorubicin accumulation
The ability of cancer cells to become resistant to chemotherapies makes treatment
difficult, resulting in poor patient outcome (20). Since KISS1R positively regulates
EGFR, and EGFR has been shown to increase cancer cell survival and drug resistance,
we next sought to determine if KISS1R regulated drug resistance as well (20). In order to
determine a role for KISS1R in the regulation of drug resistance, we first examined the
effect of KISS1R overexpression in SKBR3 cells on intracellular accumulation of the
chemotherapeutic, doxorubicin. SKBR3 pFLAG and SKBR3 FLAGKISS1R cells were
treated with doxorubicin and intracellular drug accumulation was assessed. Doxorubicin
is a traditional chemotherapy, which autofluoresces red, thus allowing a simple
assessment of intracellular drug concentrations (21).

We observed that doxorubicin

accumulation in SKBR3 FLAGKISS1R cells was decreased, compared to the vector
control cells (Figure 2.7). These results indicate that KISS1R expression may regulate
the uptake or efflux of doxorubicin in SKBR3 cells.
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Figure 2.7. KISS1R overexpression inhibited doxorubicin accumulation in SKBR3
breast cancer cells. Representative confocal images showing intracellular doxorubicin
fluorescence (red) in SKBR3 vector controls (top) and SKBR3 FLAGKISS1R cells
(bottom). Cells were treated with 1 µM doxorubicin, for 2 hours and accumulation was
visualized by confocal microscopy. Scale bars, 20 µm. Hoechst was used as a nuclear
stain (blue). Differential interface contrast (DIC) images shown on right (n=4).
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KISS1R overexpression stimulated the expression of drug efflux transporters
Doxorubicin has been shown to be a substrate for drug efflux transporters BCRP,
MRP1 and MRP4, and overexpression of these efflux transporters has been associated
with increased cellular resistance (22).

Since we observed decreased doxorubicin

accumulation in SKBR3 FLAGKISS1R cells, we next investigated the expression of drug
efflux transporters by Western blot analysis and RT-qPCR. Overexpression of KISS1R
in SKBR3 cells significantly increased expression of BCRP, MRP1 and MRP4 compared
to controls (Figure 2.8A). We also found a significant increase in BCRP mRNA in
SKBR3 FLAGKISS1R cells compared to controls, however, no change in mRNA levels
were observed for MRP1 or MRP4, upon overexpression of KISS1R (Figure 2.8B).
Interestingly, treating SKBR3 FLAGKISS1R or MDA-MB-231 cell with P-234, a
KISS1R antagonist, resulted in lower levels of BCRP mRNA, compared to cells treated
with the vehicle control (Figure 2.9). P-234 treatment of SKBR3 FLAGKISS1R cells
did not, however, decrease MRP1 mRNA expression (Supplementary Figure 3). This
data suggests that KISS1R positively regulates the expression of drug efflux transporters,
which could be one mechanism by which KISS1R signaling may regulate drug resistance.
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A

B

Figure 2.8. KISS1R overexpression increased endogenous levels of drug efflux
transporters in SKBR3 cells. A) Representative Western blots showing expression
levels of BCRP, MRP4, MRP1 in SKBR3 pFLAG and SKBR3 FLAGKISS1R cells (n=35). Western blot analysis performed with mouse anti-BCRP, rat anti-MRP4 and mouse
anti-MRP1. Densitometric analysis of Western blot expression normalized to β-actin.
Student’s unpaired T-test: *, P<0.05. Columns represent mean protein expression ± SEM.
B) BCRP, MRP4, and MRP1 mRNA expression in SKBR3 pFLAG and SKBR3
FLAGKISS1R cells. Total RNA was isolated from SKBR3 cells and RT-qPCR was
performed using primers for BCRP, MRP4, MRP1 and GAPDH (n=5). Student’s
unpaired T-test: *, P<0.05. Columns represent mean relative mRNA expression,
normalized to GAPDH ± SEM.

!

69!

A

B

Figure 2.9. P-234 pretreatment decreased BCRP mRNA expression in breast cancer
cells. BCRP mRNA expression in (A) SKBR3 cells overexpressing KISS1R and (B)
MDA-MB-231 cells. Cells were treated with 1 µM P-234 or vehicle control (VEH) in
serum-free conditions for 48 hours. Total RNA was isolated from SKBR3 cells and RTqPCR was performed using primers for BCRP and GAPDH (n=3). Student’s unpaired Ttest: *, P<0.05. Columns represent mean relative mRNA expression, normalized to
GAPDH ± SEM.
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KISS1R signaling promoted drug resistance
To further evaluate if KISS1R signaling promotes chemoresistance, MTT cell
viability assays were conducted in the presence of graded concentrations of doxorubicin
for 48 hours (23). We found that SKBR3 FLAGKISS1R cells displayed increased cell
survival in the presence of doxorubicin, compared to SKBR3 pFLAG cells (Figure
2.10A). When SKBR3 FLAGKISS1R cells were treated with P-234, the dose response
graph shifted to the left, indicating a decrease in cell viability similar to the response
observed in SKBR3 pFLAG cells (Figure 2.10A). Similarly, pretreatment of SKBR3
FLAGKISS1R with MK-571 (an inhibitor of MRP1 and MRP4) or with a cocktail of
inhibitors against all of the drug efflux transporters, decreased cell viability of SKBR3
FLAGKISS1R cells to levels observed in SKBR3 pFLAG cells (Figure 2.10B-C).
SKBR3 FLAGKISS1R cells had a significantly higher IC50 values when compared to
pFLAG, and treatment of SKBR3 FLAGKISS1R cells with KISS1R antagonist or drug
efflux transporter inhibitors restored cell sensitivity to doxorubicin (Figure 2.10D).
The ability of KISS1R signaling to regulate drug resistance was tested in two
other mammary cell lines. The non-malignant MCF10A mammary epithelial cells have
low endogenous KISS1R expression and therefore FLAGKISS1R was stably
overexpressed in these cells, which promoted EMT and increased cell invasion, as
previously described (1) (Figure 2.10A). The TNBC, MDA-MB-231 metastatic breast
cancer cells have high levels of endogenous expression (Figure 2.10A).

MCF10A

FLAGKISS1R cells and MDA-MB-231 cells were pretreated overnight with P-234 and
then treated with graded concentrations of doxorubicin. We observed, that similar to
SKBR3 FLAGKISS1R cells, MCF10A FLAGKISS1R cells had decreased sensitivity to
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doxorubicin, compared to controls. Additionally, we found that treatment of MCF10A
FLAGKISS1R cells and MDA-MB-231 cells with P-234 increased drug sensitivity
(Figure 2.11B). MCF10A FLAGKISS1R cells had a significantly higher IC50 values
when compared to MCF10A pFLAG cells, which was then decreased upon P-234
treatment (Figure 2.11C). Similarly, MDA-MB-231 cells had a significantly lower IC50
value upon P-234 treatment (Figure 2.11C). Overall, these results suggest that KISS1R
expression and signaling contributes to drug resistance in ERα-negative mammary
epithelial and breast cancer cells.
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A

B

C

D

Figure 2.10. KISS1R signaling promoted drug resistance in SKBR3 breast cancer
cells as determined using MTT cell viability assays. A) SKBR3 pFLAG or
FLAGKISS1R cells were pretreated with 1 µM P-234 (KISS1R antagonist) overnight or
left untreated. Cell viability was normalized to matching vehicle concentrations
(DMSO). B) Cells were pretreated for 10 minutes with 50 µM MK-571 (MRP1/4
inhibitor) or left untreated. Cells were then treated with varying concentrations of
doxorubicin. SKBR3 pFLAG cells were used as a control (n=5-7). C) FLAGKISS1R
cells were pretreated for 10 minutes with drug efflux transporter inhibitory cocktail.
Cells were then treated with varying concentrations of doxorubicin with and without drug
efflux transporter inhibitors. Quantification of cell viability was normalized to matching
vehicle concentrations (DMSO). Two-way ANOVA followed by a Bonferonni post hoc
test: a, P<0.05 for pFLAG vs FLAGKISS1R; b, P<0.05 FLAGKISS1R+P234 vs
FLAGKISS1R; c, P<0.05 for FLAGKISS1R+MK-571 vs FLAGKISS1R; d, p<0.05 for
FLAGKISS1R+Cocktail vs FLAGKISS1R. D) Half of the maximal inhibitory
concentration (IC50) was calculated for each individual curve. One-way ANOVA
followed by Dunnet’s multiple comparison test: *, P<0.05.
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Figure 2.11. KISS1R signaling induced drug resistance in non-malignant breast
cells and TNBC cells. A) Representative Western blots of protein expression of KISS1R
in MCF10A pFLAG and FLAGKISS1R and MDA-MB-231 breast cancer cells. B)
MCF10A pFLAG or FLAGKISS1R and MDA-MB-231 cells were pretreated with 1 µM
P-234 (KISS1R antagonist) overnight or left untreated. Quantification of cell viability
was normalized to matching vehicle concentrations (DMSO) (n=5-7). C) Half of the
maximal inhibitory concentration (IC50) was calculated for each individual curve. Oneway ANOVA followed by Dunnet’s multiple comparison test: *, P<0.05; Student’s
unpaired T-test: *, P<0.05.
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KISS1R overexpression decreased sensitivity to erlotinib
In 41-71% of TNBC patients, tumours overexpress EGFR, which is linked to the
acquisition of a more invasive phenotype (24-27).

Small-molecular inhibitors that

compete with ATP for intracellular domain binding to EGFR have been developed, such
as erlotinib, which is a TKI that is currently used to treat non-small cell lung cancer,
pancreatic cancer and is in clinical trials for breast cancer patients. We investigated if
KISS1R signaling promotes resistance to erlotinib in human breast cancer cells. Indeed,
we observed that SKBR3 FLAGKISS1R cells had increased resistance to erlotinib
(Figure 2.12A).

When the IC50 values were evaluated, FLAGKISS1R cells had a

significantly higher inhibitory concentration, compared to pFLAG control cells (Figure
2.12B). Our data thus indicates that KISS1R positively regulates EGFR levels and can
lead to increased resistance to anti-EGFR therapies in ERα-negative breast cancer cells.
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Figure 2.12. Overexpression of KISS1R in SKBR3 cells decreased cell sensitivity to
erlotinib. A) SKBR3 cells were treated with varying concentrations of erlotinib (n=8).
Quantification of cell viability was normalized to matching vehicle concentrations
(DMSO). Two-way ANOVA followed by a Bonferonni post hoc test: *, P<0.05. B) Half
of the maximal inhibitory concentration (IC50) was calculated for each individual curve.
Student’s unpaired T-test: *, P<0.05.
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KISS1R overexpression increased prosurvival signaling
Two signaling cascades commonly dysregulated in human carcinomas are the
PI3K/Akt and Ras/ERK pathways (28, 29). Up-regulation of pathways that promote cell
proliferation, survival and apoptosis, can lead to drug resistance (30). We first observed
that SKBR3 FLAGKISS1R cells expressed significantly greater levels of anti-apoptotic
protein, survivin, and increased the activity of prosurvival signaling molecules such as
Akt and ERK, compared to controls (Figure 2.13). This increase in prosurvival protein
expression and activity could be one mechanism by which KISS1R signaling appears to
regulate drug resistance in breast cancer cells.
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Figure 2.13. KISS1R overexpression increased survivin and MAPK/ERK pathways
in SKBR3 cells. Representative Western blots showing expression levels of survivin,
ERK 1/2 and Akt (n=3-5). Western blot analysis performed with rabbit anti-survivin,
rabbit anti-pERK, rabbit anti-ERK, rabbit anti-pAkt and rabbit anti-Akt antibodies.
Quantification of Western blot expression normalized to β-actin. Student’s unpaired Ttest: *, P<0.05. Columns represent mean protein expression ± SEM.
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KISS1R signaling stimulated AXL expression and activity
AXL is a member of the TAM receptor family of receptor tyrosine kinases and
has been shown to stimulate breast cancer cell invasion, EMT, as well as drug resistance
to doxorubicin and anti-EGFR therapies (31, 32).

Thus, we investigated whether

KISS1R signaling regulates drug resistance via AXL.

We found that SKBR3

FLAGKISS1R cells had increased AXL protein and mRNA expression, compared to
pFLAG control cells (Figure 2.14A-B). To evaluate a role for KISS1R signaling in
regulating AXL mRNA expression, SKBR3 FLAGKISS1R were treated with P-234 and
we observed that this led to decreased AXL mRNA (Figure 2.14B). Similarly, treatment
of TNBC MDA-MB-231 cells with P-234 significantly reduced AXL mRNA expression,
compared to cells treated with the vehicle control (Figure 2.14C).
Since GPCRs are known to activate receptor tyrosine kinases, we investigated if
KISS1R signaling led to AXL activation. Stimulation of MDA-MB-231 cells with 100
nM of KP-10 appeared to increase AXL phosphorylation (Figure 2.15).

This

phosphorylation was diminished, when cells were treated with the KISS1R antagonist P234 (Figure 2.15). Overall, these findings indicate that KISS1R up-regulates AXL
protein and mRNA expression, and may increase AXL activity in breast cancer cell lines.
Thus AXL may play a role in KISS1R-induced breast cancer drug resistance.
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A

B

C

Figure 2.14. KISS1R regulated AXL expression in human breast cancer cells. A)
Representative Western blot showing overexpression of KISS1R in SKBR3 breast cancer
cells results in increased AXL expression (n=6). Western blot analysis performed using
rabbit anti-AXL antibody. Quantification of Western blot expression normalized to βactin. Student’s unpaired T-test: *, P<0.05. Columns represent mean protein expression
± SEM. B) KISS1R activity regulates AXL mRNA in SKBR3 pFLAG and SKBR3
FLAGKISS1R cells analyzed by RT-qPCR. SKBR3 pFLAG and SKBR3 FLAGKISS1R
cells were serum-starved for 48 hours with the presence of 1 µM P-234 or vehicle control
(n=3). Two-way ANOVA followed by Bonferroni post-hoc test: a, P<0.05 for pFLAG
VEH vs FLAGKISS1R VEH; b, P<0.05 for FLAGKISS1R VEH vs FLAGKISS1R P234; c, P<0.05 for FLAGKISS1R P-234 vs pFLAG P-234. C) AXL mRNA in MDA-MB231 cells. Cells were serum-starved for 48 hours with the presence of 1 µM P-234 or
vehicle control. Total RNA was isolated and RT-qPCR was performed using primers for
EGFR and GAPDH (n=3). Student’s unpaired T-test: *, P<0.05. Columns represent
mean relative mRNA expression, normalized to GAPD ± SEM.
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Figure 2.15. KISS1R signaling activated AXL in MDA-MB-231 cells. MDA-MB-231
cells treated with 100 nM KP-10 for 0, 5 or 15 minutes, in the presence or absence of 1
µM P-234. AXL was imunoprecipitated and blots were probed with phosphorylated and
total AXL. Quantification of phosphorylated AXL expression normalized to total AXL
expression (n=2). Columns represent mean protein expression ± SEM. Contributed by
Magdalena Dragan.
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KISS1R promoted drug resistance via AXL
To investigate a role for AXL in KISS1R-induced drug resistance, AXL protein
was depleted using siRNA in SKBR3 FLAGKISS1R cells. As AXL protein expression
decreased, protein expression of KISS1R and EGFR remained unchanged (Figure
2.16A).

Additionally, AXL knockdown in SKBR3 FLAGKISS1R cells restored

chemosensitivity when compared to controls (Figure 2.16B). When the IC50 values were
evaluated for all cell lines and treatments, FLAGKISS1R siAXL cells had a significantly
lower inhibitory concentration when compared to FLAGKISS1R control cells (Figure
2.16C).

Overall, these findings suggest that KISS1R signals via AXL to induce

chemoresistance.

Surprisingly, however, we did not see a change in drug efflux

transporter expression in SKBR3 FLAGKISS1R cells upon depletion of AXL expression
(Figure 2.17).
Since AXL has been known to play critical roles in EMT, and EMT is linked to
drug resistance of many types of cancer cells (33), we determined if AXL depletion in
SKBR3 FLAGKISS1R cells regulated the expression of markers of EMT. We found that
AXL knockdown resulted in a significant decrease in Snail-Slug protein expression, but
not vimentin, compared to control cells (Figure 2.17). Overall, these results suggest that
AXL activity and expression is up-regulated by KISS1R expression and signaling, and
that AXL may promote drug resistance by regulating EMT.
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A

B

C

Figure 2.16. Depletion of AXL in FLAGKISS1R cells restored chemosensitivity. A)
Representative Western blots showing protein expression of AXL, KISS1R, EGFR and
efflux transporters in FLAGKISS1R cells transfected with AXL siRNA (n=3-6).
Student’s unpaired T-test: *, P<0.05. B) FLAGKISS1R cells transfected with AXL
siRNA or scrambled control were treated with graded concentrations of doxorubicin
(n=3). Quantification of cell viability was normalized to matching vehicle concentrations
(DMSO). Two-way ANOVA followed by a Bonferonni post hoc test: a, P<0.05 for
pFLAG vs FLAGKISS1R Scrambled; b, P<0.05 for FLAGKISS1R siAXL vs
FLAGKISS1R Scrambled; C) Half of the maximal inhibitory concentration (IC50) was
calculated for each individual curve. One-way ANOVA followed by Dunnet’s multiple
comparison test: *, P<0.05
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Figure 2.17. Depletion of AXL in FLAGKISS1R cells did not affect efflux
transporter expression but partially reversed EMT. Representative Western blots
showing endogenous protein expression of AXL, BCRP, MRP4, MRP1, vimentin and
Snail-Slug in FLAGKISS1R cells transfected with AXL siRNA, compared to
FLAGKISS1R cells transfected with control siRNA (n=3). Quantification of Western
blot expression normalized to β-actin. Student’s unpaired T-test: *, P<0.05. Columns
represent mean protein expression ± SEM.
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3.1 Summary of Novel Findings and Conclusions
Although recent studies indicate that KISS1R signaling correlates positively with
breast tumour progression and metastatic potential (1-4), it is unknown whether KISS1R
stimulates breast cancer cell drug resistance. Our data suggest that KISS1R signaling
increases EGFR expression and promotes drug resistance of ERα-negative breast cancer
cells. We show for the first time that KISS1R increases breast cancer cell resistance to
the conventional chemotherapy, doxorubicin, as well as the anti-EGFR therapy, erlotinib.
This increased resistance may be due to a KISS1R-dependent up-regulation of drug
efflux transporter expression and function as well as increased expression and activation
of AXL. Since KISS1R signaling is now implicated in the promotion of metastasis and
drug resistance, two major factors leading to poor breast cancer patient prognosis, it may
be an extremely important drug target, which could improve treatment of TNBC patients.
Objective #1: To investigate if KISS1R signaling positively regulates EGFR expression
and to begin to elucidate the molecular mechanism
We demonstrated that KISS1R overexpression in SKBR3 breast cancer cells
resulted in increased EGFR mRNA and protein expression. Furthermore, our results
suggest that KISS1R activity regulated this process since EGFR mRNA levels were
reduced in the presence of the KISS1R antagonist. Interestingly, we found that KISS1R
overexpression increased nuclear localization of transcription factors SP-1 and NF-κB,
both of which have been shown to up-regulate EGFR transcription (5).

KISS1R

overexpression also resulted in increased binding of SP-1 and RNA Pol II to the EGFR
promoter, as demonstrated by ChIP. Overall these results indicate that KISS1R promotes
EGFR transcription in ERα-negative breast cancer cells.
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Objective #2: To determine if KISS1R signaling promotes breast cancer drug resistance
We demonstrated that KISS1R signaling resulted in decreased doxorubicin
accumulation in SKBR3 cells, and lowered the sensitivity of cells to this conventional
chemotherapeutic, through up-regulating drug efflux transporter expression and function.
KISS1R overexpression also increased drug resistance to erlotinib, an anti-EGFR
therapeutic. These results show for the first time that KISS1R signaling promotes drug
resistance. Additionally, KISS1R signaling increased the expression of anti-apoptotic
proteins including Akt and survivin. We identified AXL as new signaling partner in the
KISS1R pathway, and demonstrated that KISS1R signaling positively regulates AXL
expression and activity. AXL depletion in KISS1R overexpressing cells restored
chemosensitivity, possibly by the partial reversal of EMT. Thus, our results reveal
potential mechanisms by which KISS1R signaling promotes breast cancer drug
resistance, by regulating the expression of drug efflux transporters and also by activating
AXL.

3.2 Contributions of Research to Current State of Knowledge
Cell surface receptors are an integral part of signaling systems, allowing
extracellular signals to be turned into intracellular responses. Two major classes of these
cell surface receptors include GPCRs and RTKs (6). Interestingly, cross-communication
between these two receptor groups can occur, synergistically or antagonistically,
facilitating many complex signaling responses and resulting in a wide range of
physiological and pathological cellular events (6, 7). The activation of GPCRs has been
shown to stimulate RTK activity by a molecular mechanism termed ‘transactivation’.
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GPCR signaling was first demonstrated to increase RTK activity when Rat-1 fibroblasts
were stimulated with GPCR agonists, endothelin-1, lysophasphatic acid and thrombin,
and EGFR tyrosine phosphorylation rapidly increased (8). It is now understood that
GPCRs can transactivate RTKs through a variety of mechanisms, including increasing
intracellular reactive oxygen species, MMP-dependent release of RTK ligands, increased
Ca2+ mobilization, or by non-RTKs, including Src (6, 9).
EGFR is an RTK that is overexpressed in numerous cancers. EGFR signaling
results in increased cell proliferation, invasion and metastasis and angiogenesis (9, 10).
Specifically in TNBC, EGFR overexpression is seen in 41-71% of patients (11-14). This
makes EGFR a highly favourable drug-target due to its role in many oncogenic pathways,
specifically in TNBC patients, where targeted therapy is limited.

Unfortunately,

however, inhibition of EGFR alone, targeting either the extracellular domain or the
tyrosine kinase domain, has resulted in poor clinical outcomes due to acquired resistance
to these agents (15). Our lab has previously established a role of KISS1R in regulating
breast cancer cell invasion via EGFR transactivation in TNBC cells (2, 3). Our previous
work demonstrated that KP-10 transactivates EGFR, via scaffolding proteins β-arrestin 2
and IQGAP, leading to breast cancer cell invasion (2, 3). Since KISS1R appears to be
increasing breast cancer cell invasion in an EGFR-dependent mechanism, perhaps
targeting both receptors simultaneously could lead to increased efficacy compared to
monotherapies.
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Role of KISS1R Signaling in Regulating EGFR Expression in Breast Cancer
EGFR protein is overexpressed in TNBC patients resulting in increased EGFR
signaling and therefore tumourigenesis in TNBC patients (11-14). EGFR overexpression
in TNBC patients is rarely caused by increased gene copy number or activating mutations
(16, 17). The overexpression of EGFR is therefore possibly due to regulation at the
transcriptional and translational level. Similarly, in breast cancer cell lines, it has been
shown that EGFR mRNA levels correlate with the amount of receptor protein expressed,
and that these differences are controlled at the transcriptional level (18). Due to the short
half-life of EGFR mRNA (approximately 1-2 hours), post-transcriptional regulation,
possibly through modification of mRNA stability, is thought to play only a small role in
EGFR protein expression (19, 20). Therefore, variations in transcription rates are thought
to be the major determining factor regulating EGFR protein expression.

We have

demonstrated that KISS1R signaling up-regulates EGFR mRNA and protein levels and
this was regulated by KISS1R activity, since this effect was inhibited in the presence of
the KISS1R antagonist.

Surprisingly, EGFR mRNA expression in SKBR3

FLAGKISS1R cells was not further increased with KP-10 stimulation (Supplementary
Figure 1). The lack of further increase in EGFR mRNA with KP-10 treatment could be
due to the high basal kisspeptin expression seen in SKBR3 FLAGKISS1R cells. Thus
these findings indicate that KISS1R signaling regulates EGFR expression by increasing
EGFR gene transcription.
The EGFR gene has been well characterized, spanning 110 kilobases and
consisting of 26 exons (21). The promoter region lacks the traditional TATA or CAAT
boxes, the most common promoter elements, and therefore transcription initiation begins
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at 6-7 sites in the 50-250 base pairs region upstream of the ATG translation start codon
(22). Interestingly, the most common transcription initiation site in vivo is more distal,
compared to the most common in vitro transcriptional initiation site, located
approximately 50 base pairs upstream of the start codon (19). A number of transcription
factors have been shown to bind to the EGFR promoter region, including TCF, ETF1-2,
GCF, ETR, AP-2 and SP-1 and NF-κB (19). Additionally, EGFR gene transcription is
also regulated by a number of hormones and growth factors, including progesterone and
vitamin D (19, 23).
Although the EGFR promoter region has been characterized since the 1980s and
some mechanisms have been proposed for increased EGFR transcription, the molecular
mechanisms by which EGFR transcription is increased in TNBC patients is largely
unknown. Our results demonstrate that KISS1R signaling promotes EGFR transcription
and expression possibly by regulating transcription factors SP-1 and NF-κB.
Specifically, four SP-1 binding sites were found upstream of the EGFR start site and it
was demonstrated that SP-1 binding to the EGFR promoter region was required for
maximal expression (5). Additionally, SP-1 and EGFR expression in human breast
tumours was correlated with increased tumour grade and poor prognosis (24). Similar
findings were shown in human gastric carcinoma cell lines and gastric carcinoma tissues
as well (25). Furthermore, we have demonstrated that recruitment of SP-1 and RNA Pol
II to the EGFR promoter was increased with KISS1R overexpression in breast cancer
cells. To the best of our knowledge, this is the first study to demonstrate KISS1R
enhances SP-1 and RNA Pol II binding in order to increase EGFR expression. Although
we have only investigated SP-1 and RNA Pol II binding at the SP-1 binding site most
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proximal to the start codon (our primer encompassed -129 to -23 base pairs), the most
common transcription initiation start site in vitro is also located within that region (22).
Additionally, RNA Pol II enrichment on the EGFR promoter has also been shown to
occur within -240 to -70 base pairs upstream of the start codon in LNCaP prostate cancer
cells, which correlated with increased EGFR expression (26). Lastly, characterization of
the EGFR promoter by deletion analysis revealed that only the region between -178 and 16 base pairs was required to have sufficient promoter activity and EGFR expression
(27). Overall, our studies uncover a role for KISS1R in not only activating EGFR, but
also up-regulating EGFR expression, via increased SP-1 nuclear recruitment of SP-1.
KISS1R may be an excellent receptor to target in order to decrease EGFR-driven
tumourigenesis, particularly in TNBC patients.

KISS1R Signaling in Promoting Breast Cancer Drug Resistance
The development of drug resistance in human carcinomas is the most difficult
obstacle to overcome, specifically in patients whose primary tumour or distant metastases
have not been fully surgically removed. Uncovering the molecular mechanisms that
drive tumour drug resistance is essential in order to be able to develop targeted therapies
that can disrupt resistance and restore drug sensitivity. Although EGFR has been shown
to increase cancer cell migration and metastases, it has been shown to also promote cell
survival and drug resistance (10).

The role of EGFR in regulating tumour drug

sensitivity has been debated in the past, however, the majority of studies demonstrate
restored drug sensitivity upon EGFR inhibition (10). Blocking EGFR through antibodies
increased sensitivity of human tumour xenografts to cisplatin using human breast cancer
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cells, MDA-MB-468, and human mouth epidermal cancer cells, KD (28, 29). Baselga
and colleagues used mice with subcutaneous xenografts of A431 epidermoid carcinoma
cells to demonstrate that EGFR blockade resulted in increased sensitivity to doxorubicin.
Tumours treated with combinational therapy of doxorubicin plus an anti-EGFR inhibitory
antibody, resulted in complete eradication of tumours in all animals, whereas
monotherapies of either treatment results in only a modest reduction of tumour growth
(30).
Since our results demonstrated that KISS1R positively regulates EGFR
expression in ERα-negative human breast cancer cells, we sought to investigate if
KISS1R signaling played a role in regulating drug resistance. We found that KISS1R
signaling in SKBR3 cells promoted the intracellular accumulation of doxorubicin and
doxorubicin resistance. Using multiple cell lines (SKBR3 FLAGKISS1R, MCF10A
FLAGKISS1R and MDA-MB-231 cells) we demonstrated that KISS1R activity regulated
drug resistance, since doxorubicin sensitivity was restored in the presence of KISS1R
antagonist. We found that KISS1R signaling resulted in an up-regulation of drug efflux
transporters BCRP, MRP1 and MRP4 and the activity of these transporters was necessary
for mediating drug resistance. Currently, we do not know whether increased EGFR
expression leads to elevated levels of drug efflux transporters in ERα-negative cells.
However, other studies have reported that EGFR overexpression can regulate drug efflux
transporter-dependent multi drug resistance in cancer cells (31). When drug resistant
BCRP overexpressing MCF-7 cells were treated with apatanib, a TKI, BCRP transport
function of doxorubicin was decreased (31). Thus, KISS1R signaling leads to an increase
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in EGFR expression and this may up-regulate drug efflux transporters, which will
contribute to the multidrug resistance phenotype (Figure 3.1).
Currently, a single study has investigated a potential role for kisspeptin signaling
in cancer drug resistance. Jiffar and colleagues developed a cisplatin resistant head and
neck squamous cell carcinoma (HNSCC) cell line by exposing HNSCC cell lines to
escalating doses of cisplatin for 6 months (32). These cisplatin resistant HNSCC, as well
as the parental line, were utilized in a orthotopic mouse model. Cisplatin resistant cells
displayed increased primary tumour growth and increased metastasis that lead to
decreased overall survival (32). Next, through real-time PCR and Western blot analysis,
KISS1 mRNA expression was shown to be decreased in cisplatin resistant HNSCC cells
compared to the control. Similarly, through small interfering RNA (siRNA) depletion of
KISS1 in the parental HNSCC cell line, cells became partially resistant to cisplatin (32).
Overall, this study suggests a role for KISS1 expression in regulating cisplatin drug
resistance as well as metastasis in HNSCC. Although this study is in contrast to our
current findings, kisspeptin/KISS1R signaling in ERα-negative breast cancer has shown
to be detrimental, promoting cell invasion, breast tumour grade, as well as poor patient
prognosis, whereas the KISS1R system is anti-metastatic in other cancers. Therefore it
should not be surprising that the role of kisspeptin/KISS1R signaling in breast cancer
drug resistance differs from the role this signaling system plays in other tumour types.

KISS1R Signaling Promotes Cell Survival
Two of the most dysregulated signaling cascades in human carcinomas are the
PI3K/Akt and Ras/ERK pathways (33, 34). These pathways are cascades of kinases that
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become active through phosphorylation and are therefore regulated by other kinases,
phosphatases as well as scaffolding proteins (35). These pathways play key roles in
promoting cell proliferation, survival and apoptosis, and therefore overactivation of these
pathways can lead to drug resistance (36).

Not only are both of these pathways

downstream of growth factor receptors, including EGFR, which are commonly
overexpressed in cancers, but also many downstream components can be altered, leading
to increased tumourigenesis and resistance to therapies (35). Here, we have reported that
KISS1R overexpression in SKBR3 cells could increase cell survival by increasing
PI3K/Akt and Ras/ERK pathway signaling as seen by an increase in phosphorylated Akt
and ERK proteins. Although in our system, we can’t rule out that the increase in
phosphorylated Akt and ERK could be due to the overexpression and increased activity
of EGFR, both Akt and ERK have been shown to signal downstream of KISS1R as well
(1).
In addition to increasing these cell survival signaling cascades, we found that
KISS1R overexpression increased the expression of the anti-apoptotic protein, survivin.
Survivin, a member of the Inhibitors of Apoptosis Proteins family, controls cell
proliferation, inhibition of apoptosis as well as promotion of angiogenesis (37). The
overexpression of survivin has been demonstrated in numerous tumours, including breast
(37). Patients shown to have increased survivin expression are associated with shorter
survival, increased risk of recurrence and resistance to therapies (37). Interestingly, the
PI3K/Akt pathway has been shown to up-regulate survivin expression in breast cancer, as
sustained Akt activation resulted in a dramatic increase in surivivin expression (38).
Additionally, survivin expression is positively correlated with EGFR expression in breast
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tumours (38). Lastly, the PI3K/Akt pathway has also been implicated in facilitating drug
resistance through the up-regulating drug efflux transporter, P-gp in breast cancer cells
(39).

Treatment of MCF-7 doxorubicin resistant breast cancer cells, with a PI3K

inhibitor, decreased survivin as well as P-gp expression and restored cell sensitivity to
doxorubicin (39). Although we did not see an increase in P-gp expression upon KISS1R
overexpression (Supplementary Figure 2), perhaps the PI3K/Akt pathway could be
regulating other drug efflux transporters as well. Our findings indicate that KISS1R
could be signaling through EGFR to increase survivin as well as drug efflux transporter
expression and therefore promote drug resistance through multiple mechanisms.

KISS1R Signaling Up-regulates AXL leading to Drug Resistance
AXL is another RTK that has been implicated in regulating tumourigenesis in
many cancers, due to its role in promoting cell proliferation and survival. Overexpression
of AXL has been reported in numerous cancers, including breast, and has been shown to
correlate with poor patient prognosis, as well as increased invasiveness and xenograft
growth of human cancers (40). Interestingly, both of the oncogenic signaling pathways,
PI3K/Akt and Ras/ERK, also signal downstream of AXL (40). Our results indicate that
KISS1R signaling can positively regulate AXL expression of human breast cancer cells,
as demonstrated in SKBR3 and MDA-MB-231 cells. By up-regulating AXL expression,
which can lead to increased signaling via the P13K/Akt and Ras/ERK pathways, KISS1R
signaling can promote drug resistance of breast cancer cells. It is also therefore not
surprising that AXL overexpression has also been shown to promote drug resistance of
breast cancer (41). These studies support our findings that in SKBR3 FLAGKISS1R
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cells, AXL depletion restores sensitivity to doxorubicin. Surprisingly, however, is that in
AXL depleted SKBR3 FLAGKISS1R cells, there was no change in drug efflux
transporter expression. This could possibly be due to the very long half-life of the drug
efflux transporters (42), and therefore the 48-hour time point of AXL siRNA transfection
was not long enough to see an effect the protein level of these transporters.
Alternatively, since there was no change in drug efflux transporter expression
upon AXL depletion, we explored other mechanisms by which AXL could be regulating
drug resistance. AXL can positively regulate EMT in many cancers (43-45). We have
demonstrated previously, that KISS1R signaling also promotes an EMT-like phenotype
(2). In order to elucidate if KISS1R is regulating EMT via AXL, expression of markers
of EMT, including vimentin and Snail-Slug were investigated in AXL depleted SKBR3
FLAGKISS1R cells. Although vimentin protein expression was not changed, Snail-Slug
was significantly decreased upon AXL depletion. Thus we propose that AXL may
promote drug resistance by regulating EMT. This is supported by Li and colleagues, who
demonstrated that depletion of AXL in MDA-MB-231 cells decreased PI3K/Akt
signaling, resulting in a decrease of Slug expression, which suppressed breast cancer cell
invasion and restored drug sensitivity (46). Additionally, although AXL signaling has
been shown to increase vimentin protein expression in DU145, human prostate cancer
cells, AXL-induced vimentin expression was through a Snail-Slug-dependent
mechanism, as vimentin was not overexpressed when Snail-Slug was depleted (47). Our
short length of AXL depletion, 48 hours, may have only been enough time to decrease
Snail-Slug expression, whereas extended AXL silencing may result in decreased
expression of proteins downstream of Snail-Slug, including vimentin.
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EMT has been shown to drive drug resistance in a number of human breast cancer

cells (48). EMT-mediated drug resistance is through a variety of mechanisms, some
being the positive regulation of drug efflux transporter expression and activity, and
another being through increasing breast cancer cell stem-like properties (48). Fang and
colleagues reported that by transfecting MCF-7 and MCF-10A breast cancer cells with
Twist, a transcription factor that promotes EMT, cells had increased stem-like profiles,
indicated by a high expression of CD44 and low expression of CD24 (CD44+/CD24-)
(49). Additionally, breast cancer cells exogenously expressing Twist also had an upregulation of MRP1, again, implicating EMT in drug resistance (49).

Similarly,

exogenous expression of Snail, in non-tumourigenic human mammary epithelial cells,
HMLE, resulted cells with self-renewing capacities and a CD44+/CD24- profile (50).
These studies and our findings indicate that the ability of KISS1R to up-regulate AXL
could be promoting drug resistance in an EMT-mediated pathway. Whether KISS1R
signaling promotes stemness is currently unknown and studies investigating this are
underway.

3.3 Limitations and Future Directions
Our research has revealed a possible role for KISS1R signaling in breast cancer
drug resistance. Although we have proposed many potential mechanisms, most of which
are regulated by EGFR and AXL, further research must be performed to fully understand
how kisspeptin/KISS1R signaling is regulating drug resistance. Specifically, a loss-offunction approach can be taken to determine whether depletion of KISS1R in TNBC cells
(MDA-MB-231 and Hs578t) can restore drug sensitivity.

Additionally, the use of
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alternative experiments that also assess cell sensitivity to therapies, such as the
clonogenic cell survival assay, could be performed in order to further validate the role of
KISS1R in promoting drug resistance (51). Muir and colleagues initially demonstrated
that nitric oxide mimetics could sensitize MDA-MB-231 breast cancer cells, cultured in a
monolayer as well as spheroids, to doxorubicin through clonogenic assay (52).
Performing spheroid clonogenic assays better mimics the heterozygosity of tumour cells
in vivo, due to the different rates of proliferation of the cells on the outer and inner layer
of the spheroids (53).
Further knowledge regarding EGFR regulation could also be obtained by
determining the SP-1 nuclear recruitment on other SP-1 sites, or examining the role of
additional transcription factors, such as NF-κB, on the EGFR promoter by ChIP
experiments. Additionally, the effect of KISS1R signaling on SP-1 nuclear recruitment
could be examined by pre-treating SKBR3 FLAGKISS1R cells with KISS1R antagonist,
P234, or by depleting KISS1R in TNBC cells.
Lastly, to investigate if KISS1R promotes drug resistance in vivo, studies must be
performed in an animal model.

Subcutaneous xenografts could be established in nude

mice, by injecting SKBR3 FLAGKISS1R and control cells. Once tumours reached a
certain size, animals would be treated with doxorubicin and primary tumour size would
be measured to determine the sensitivity of SKBR3 cells to doxorubicin. Tumour tissue
could be collected and immunohistochemistry could be performed to see if kisspeptin or
KISS1R expression correlated with drug resistance.

Similar xenograft studies were

performed with BT-474 breast cancer cells in order to determine if trastuzumab resistance
correlated with HER-2 overexpression (54).
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3.4 Conclusions
Our results demonstrate for the first time that KISS1R signaling regulates human
breast cancer drug resistance to conventional therapeutics such as doxorubicin as well as
the anti-EGFR therapy, erlotinib.

This KISS1R-induced drug resistance could be

mediated through regulating EGFR and/or AXL expression, leading to increased drug
efflux transporter expression and increased cell survival signaling (Figure 3.1). Thus,
this study has identified KISS1R as a novel therapeutic to target human breast cancer
drug resistance.
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Figure 3.1. Our proposed model for KISS1R signaling promoting drug resistance in
TNBC. KISS1R signaling increases the expression of drug efflux transports as well as
the expression and activity of RTKs, EGFR and AXL. AXL has been shown to increase
drug resistance. Additionally, KISS1R signaling regulates a variety of cell survival
pathways leading to increased P13K/Akt and Ras/ERK signaling, as well as increased
survivin expression. KISS1R signaling also increases EMT and the expression of drug
efflux transporters. Taken together, activation of these pathways can promote drug
resistance of breast cancer cells.
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Supplementary Figures

Supplementary Figure 1. Kisspeptin-10 stimulation does not alter EGFR mRNA
expression in SKBR3 cells. EGFR mRNA in SKBR3 pFLAG and FLAGKISS1R cells
analyzed by RT-qPCR. SKBR3 pFLAG and FLAGKISS1R cells were grown in the
presence of 100 nM KP-10 for 24, 48 or 72 hours in complete media (n=3). Columns
represent mean relative mRNA expression, normalized to GAPDH ± SEM.

Supplementary Figure 2. KISS1R overexpression did not increase P-gp protein
expression in SKBR3 cells. Relative protein expression of P-gp as identified by
Western blot analysis (n=3). Columns represent mean relative protein expression,
normalized to actin ± SEM.
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Supplementary Figure 3. P-234 treatment did not alter MRP1 mRNA expression in
SKBR3 FLAGKISS1R cells. MRP1 mRNA expression in SKBR3 pFLAG and SKBR3
FLAGKISS1R cells treated in serum free media for 48 hours in the presence of 1uM P234 or 20% acetonitrile (VEH) control. Total RNA was isolated from SKBR3 cells and
RT-qPCR was performed using primers for MRP1 and GAPDH (n=5). Columns
represent mean relative mRNA expression, normalized to GAPDH ± SEM.
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